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II. THESIS ABSTRACT
Background:  Rheumatic heart disease (RHD) remains a major public health concern in African 
countries due to the high rates of complications such as atrial fibrillation, stroke, infective 
endocarditis, and heart failure, all of which can result in premature death.  In 2015, RHD was 
estimated to affect 33 million people globally and resulted in at least 320,000 deaths, nearly all of 
which were in low and middle-income countries. Comparing to other non-communicable diseases 
(NCDs), RHD imposes economic burden on households that if measures are not in place to 
mitigate this, it can impoverish such household. However, there are several literatures on the 
intergenerational economic consequences of other chronic diseases. But, there is no study 
regarding the household economic of RHD. This mini-dissertation sets out to estimate the 
household economic impact of RHD.  
Methods: This study was a follow-on study from the Global Rheumatic Heart Disease Registry 
(REMEDY), which was a multi-center, international, hospital-based prospective registry of 
patients with RHD. It was designed as a cohort study to document the disease characteristics and 
outcomes of individuals with RHD across many countries. We recruited participants in the 
REMEDY study who were resident in Cape Town and received care at Groote Schuur Hospital 
(GSH). This study made use of patient and household member surveys to estimate the economic 
consequences of RHD among households in which REMEDY participants reside.  REMEDY 
registry participants (index cases), their caregivers, and other household members were 
considered as respondents. 100 REMEDY participants receiving care at GSH was sampled. This 
sample size was chosen to balance feasibility and precision and to align with a parallel study of 
the cost of RHD to the health system that aimed to sample medical records from the same 100 
REMEDY participants. Patient and household data collection was carried out between 
September 2017 to December 2017.  Direct costs, indirect costs, and the downstream economic 
behaviors (coping strategies) that lead to medical impoverishment and other consequences were 
estimated. Cost of illness (COI) was used to assess the effect of ill-health and health-related 
expenditure on the consumption possibilities of households.  Direct costs comprise both medical 
and non-medical costs, which may include both the financial cost of resources as well as 
opportunity costs (e.g., of capital items). Human capital approach was used to calculate indirect 
cost. Implicit in the human capital approach is the assumption that changes in health status of 
household members can be reflected by losses in productivity, and losses in income generation. 
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Productivity losses was estimated using the new South Africa minimum wage rate per month as 
proxy. Coping was estimated with the direct costs (e.g., borrowing from friends or relatives, or 
taking out formal loans) or indirect costs (e.g., intra-household labor substitution) and can be 
cost prevention strategies (e.g., ignoring illness, non-treatment) to cost management strategies 
(e.g., borrowing, selling assets, or labor substitution). Economic costs were valued in United 
State dollar (USD) converted from South African rand (ZAR) in 
 2017.  
Results:  Direct medical cost was estimated to ZAR 0, because all patients were exempt from 
medical fees. Total direct non-medical cost for outpatient and inpatient visits was estimated to be 
ZAR 27,000 (USD 2000) and 29,000 (USD 2200) (respectively) over 302 and 74 encounters 
(respectively), an average of ZAR 270 (USD 20) and ZAR 290 (USD 22) per patient (respectively).  
Indirect costs incurred over the 302 outpatient encounters and 74 hospital admissions were 
estimated to be ZAR 41,000 (USD 3100) and ZAR 26,000 (USD 1900) (respectively), an average 
of ZAR 410 (USD 31) and ZAR 260 (USD 19) per patient. Direct cost had a very high impact on 
the household and they were compelled to adopt coping. Households observed in the study 
recorded that seventeen percent of households took out loans at an average of ZAR 1200 (USD 
91) per loan (range ZAR 100 to ZAR 7000) (range USD 7 to 500).  Fifteen percent received 
financial gifts at an average of ZAR 800 (USD 61) per gift. Two percent sold assets valued at ZAR 
5600 (USD 120) on average. Five percent engaged in multiple coping strategies. Also, HH had to 
cope with indirect cost of illness as 15% of household caregivers changed jobs and 10% worked 
extra hours. About 4% of household members dropped out of school. Four percent adopted more 
than one coping strategy. A considerable share of participants reported that they had reduced 
education to take care of the affected patient. Most of the caregivers of patients with RHD were 
spouses and children, and 6 % were heads of household. The total cost of RHD to the average 
affected household is valued at about ZAR 1600 annually. In total, the overall annual economic 
impact of RHD in this sample of 100 households affected by RHD was estimated at ZAR 160,000 
(USD 12200) (ZAR 1600 per household) (USD 120), representing 4.4% of annual household 
income or 4.9% of annual household expenditure patient spending that exceeded 10% threshold 
was estimated to be 8% and increasing the threshold to 40 % of non- food expenditure reduced the 
prevalence of catastrophic spending to 4%.  
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Conclusions:  The economic impact of RHD in South Africa is substantial despite government 
efforts to provide free care. The total cost of RHD to the average affected household is valued at 
about ZAR 1600 annually. A broader and more robust range of social policies will be required to 
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Globally, noncommunicable diseases (NCDs) have been described to be one of the leading causes 
of mortality with about 80% of deaths in low- and middle-income countries (LMICs) (WHO, 2014, 
Health, 2013, Nundy and Han, 2012, Desouky et al., 2014). Rheumatic heart disease (RHD) as a 
noncommunicable disease amongst other NCDs also is fast growing in developing countries with 
very high impact (Celermajer et al., 2012). In 2008, about 36 million people died from NCDs 
including cancers (21%), cardiovascular diseases (48%), chronic respiratory diseases (12%), and 
diabetes (3%) (WHO, 2014, Health, 2013, Nundy and Han, 2012). Contrary to popular beliefs, 
many NCD deaths occur among children and working-age adults, which has brought about 
discussions on how to curb the NCD epidemic, especially through preventive interventions 
(Petersen, 2003, Desouky et al., 2014).  NCDs are projected to increase 17% globally over the next 
10 years and by 24% in Africa; by the year 2030, it is projected that 75% of global deaths will be 
due to NCDs (Health, 2013, Alwan et al., 2010).  
While infectious diseases are more commonly associated with poverty, the impact of NCDs in low 
socioeconomic status groups is very high. NCDs can create a vicious cycle where vulnerable 
individuals exposed to behavioral risk factors experience worse health, which pushes them further 
into poverty (WHO, 2014). At the same time, there are some NCDs which are endemic among the 
poor and that are largely amenable to socioeconomic development and better access to healthcare 




Rheumatic Heart Disease  
Rheumatic heart disease (RHD) is a frequent cause of cardiovascular disease among children and 
working-age adults in LMICs. RHD results from repeated episodes of acute rheumatic fever 
(ARF), a delayed complication of sore throat due to group A streptococcal infection, which mostly 
afflicts children aged 5-14 years (Sliwa et al., 2010, Otto, 2004, Cilliers, 2014).  
 RHD remains a major public health concern  in African countries because of its high rates of 
complications such as atrial fibrillation, stroke, infective endocarditis, and heart failure, all of 
which can result in premature death, including death during pregnancy (Zühlke et al., 2016). In 
2015, RHD was estimated to affect 33 million people globally and to result in at least 320,000 
deaths, nearly all of which were in LMICs (Hay et al., 2017, Naghavi et al., 2015). The high degree 
of disability and premature death from RHD is likely to reduce productivity and economic growth 
in endemic countries (Zühlke et al., 2015a, Koegelenberg et al., 2003, Watkins et al., 2016a, 
Marijon et al., 2012). RHD is most common in sub-Saharan Africa, south Asia, the Pacific Islands, 
and among indigenous populations in New Zealand and Australia (Cilliers, 2015) 
 
  Adapted from (Carapetis, 2007) 
Figure 1: RHD causality partway 
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Rheumatic heart disease causality pathway shows the prevention housings hygiene from the 
primary initial infection stage of group A streptococcal infection and progresses to the secondary 
prevention method with the use of secondary prophylaxis that is commonly used for an acute 
rheumatic fever and the use of the tertiary prevention mechanism where there will be a need for 
heart failure valve surgery Anticoagulation due to RHD. RHD could deteriorate to stoke, cardiac 
failure and finally could lead to death of the patient.    
 
Determinants of RHD 
The risk factors that have been identified for RHD are low income, overcrowding, malnutrition, 
poor sanitation, and low educational attainment, as well as poor access to primary care for 
treatment of sore throat (Carapetis et al., 2005, Marijon et al., 2012, Meira et al., 2005, Bach et al., 
1996, Longo-Mbenza et al., 1998, Sadiq et al., 2009, Dobson et al., 2012). Consequently, ARF 
that has dramatically declined in developed countries over the past 30-40 years remains high in 
LMICs (Ayoub, 1992, Carapetis and Currie, 2001, Watkins et al., 2009, Alipour et al., 2016, 
Carapetis et al., 2005, Tibazarwa et al., 2008, Nkomo, 2007, Longo-Mbenza et al., 1998). Interest 
in RHD in LMICs has grown over the past decade in the wake of a 2007 landmark report that 
demonstrated a high prevalence of RHD (30 per 1000) among school children in Mozambique; 
similar findings have been identified in countries like Uganda, Cameroon, and Malawi (Cilliers, 
2015, Marijon et al., 2012, Beaton et al., 2012, Jingi et al., 2013, Kennedy and Miller, 2013).  
RHD in South Africa 
There have been several published studies of RHD in South Africa over the past few decades. The 
prevalence of RHD was estimated using auscultation-based screening in Johannesburg (1976) and 
Cape Town (1981), where it was found to affect about seven in 1000 in school children (Zühlke et 
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al., 2015b, ). The most recent prevalence study was conducted among school children in Cape 
Town in 2016 using cardiac ultrasound-based screening; this study found that 20 in 1000 learners 
were affected (Engel et al., 2015). The prevalence and incidence of symptomatic RHD is higher 
in adults, whereas it often remains asymptomatic during childhood earlier in the course of the 
disease (Zühlke et al., 2015b). Despite these findings, there has been some progress on RHD in 
South Africa, including declines in ARF amongst children in Soweto and in Limpopo 
province(Cilliers, 2015, Cilliers, 2014). The RHD mortality rate in South Africa  decreased from 
1.27 per 100,000 population in the year 1997 to 0.7 per 100,000 in 2012 (Zühlke et al., 2015b). 
Objectives of the study 
The specific objectives of this study are to develop survey instruments to:  
1.  estimate the direct cost of RHD from the patient perspective 
2.  determine the impact of RHD on the economic and social welfare of the household measuring 
productivity and quality of life.   
3.  examine the household coping mechanisms associated with RHD 
Mini literature  
Previous studies of the economic impact of RHD 
The economic impact of RHD has been quantified by relatively few studies, none of which have 
been conducted in South Africa (Terreri et al., 2001, Soudarssanane et al., 2007, Koech and Ngeno, 
2014).  The major costs of RHD to households include out-of-pocket direct costs like laboratory 
tests, transportation, consultations, and hospital costs, as well as indirect costs like lost 
wages/salary due to absenteeism from work and loss of productivity of the caregiver and patient 
in general (Terreri et al., 2001, Soudarssanane et al., 2007, Koech and Ngeno, 2014, Robertson 
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and Mayosi, 2008). In some households, RHD is likely to affect educational attainment and thus 
employment opportunities (Koech and Ngeno, 2014). For example, in Kenya and Brazil, 67% and 
22% (respectively) of children  with RHD drop out of school (Terreri et al., 2001, Koech and 
Ngeno, 2014). This literature remains sparse and to date has failed to capture the full range of 
economic consequences, described below, that RHD can produce in affected households. 
1.2. Theoretical framework 
Methods for measuring the economic burden of disease  
The economic burden of disease can be measured using several approaches. The most frequently 
used is the “cost of illness” (COI) approach, which estimates the highest amount that could be 
potentially saved or gained by eradicating a disease (Segel, 2006b). It also assesses the cost impact 
of disease at the country, region, community, or individual level (Suhrcke et al., 2006b). COI 
studies ideally take a societal perspective on costs that incorporates health system costs and 
microeconomic effects on households. From an economic point of view, COI encompass the 
effects of disease-related disability on overall health status and quality of life (QoL) – i.e., 
productivity – as well as the financial effects (health-related expenditures) of untimely death, 
disability or injury due to corresponding disease and/ or its comorbidities (Jo, 2014). Over the past 
thirty years, studies on COI have informed health policy debates by illustrating the extent of the 
impact that an illness has on society in general (Rice, 2000, Segel, 2006b, Jo, 2014). 
In addition to the aim of measuring economic costs, COI often aim to assess the effect of ill-health 
and health-related expenditure on the consumption possibilities of households. Ill health tends to 
increase the household expenditure on health services and reduce household expenditure on non-
health related goods; very high levels of health-related expenditure can induce households to 
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liquidate assets, borrow formally or informally, or deplete savings (WHO, 2009). Further, ill health 
reduces the productivity and leisure time of other household members who look after a sick 
household member. These indirect household effects can be classified in three categories: (1) 
changes in consumption and savings, (2) effects on labour supply and labour productivity, and (3) 
effects on educational attainment and human capital accumulation. These categories serve to 
differentiate between the effects on the sick individual and the effects on other household members 
(Suhrcke et al., 2006a).Finally, the economic impact of disease is often not limited to the current 
time period. Health services and goods may be paid for via a loan or the sale of household assets 
(i.e. dis-savings), and the reduced household income, savings and assets resulting from the 
consumption of health services and goods may in turn drain investment in (physical, financial and 
human) capital, influencing consumption possibilities in the future (WHO, 2009).To assess the 
cost of illness, the household is the preferred unit of analysis for two reasons. Firstly, decisions 
about medical treatment and financial coping mechanisms are often based on negotiations within 
the household, though not necessarily from an equal bargaining position. Secondly, illness costs 
are incurred by caregivers as well as the sick individual, and all costs fall on the household budget 




Figure 2: Overview of the economic consequences of illness. Adapted from: (McIntyre et al., 
2006) 
Figure 2 above explains the analytical framework for the study on cost of illness. This describe the 
evolving experience of LMICs associated economic consequence of illness. The economic 
consequence considered the impact of diverse types of cost including direct out-of-pocket 
payment, direct medical cost, direct non-medical cost, and indirect cost on healthcare. Households 
are affected directly or indirectly as one or more member of the household has ill-health. There are 
also cost on caregiver which inform the household and individual on how they cope with the 




The objective of COI studies is to identify and measure all the costs of a particular disease, 
including the direct, indirect, and intangible dimensions (Byford et al., 2000). COI studies usually 
measure economic costs, which are the sum of opportunity costs (i.e., the lost benefits of devoting 
resources to other activities when they are employed in one activity) and accounting costs (i.e., 
cash outlays). As discussed above, economic costs can be classified as direct or indirect. Intangible 
costs, such as the value of pain, anxiety, and suffering, are also important from a social standpoint, 
but these are omitted from COI studies due to measurement challenges (Segel, 2006b, Rice D et 
al., Hodgson and Meiners, 1982, Cooper and Rice, 1976).  
Direct costs  
Direct costs are the sum of medical and non-medical costs and may include both the financial cost 
of resources as well as in some cases opportunity costs (e.g., of capital). Medical costs include 
expenditures on medical care for inpatient and outpatient care, rehabilitation, and nursing home 
care, and emergency care, as well as the associated consultation fees, diagnostic tests, prescription 
drugs and drug sundries, and medical supplies. Non-medical costs include transportation, property 
losses, relocation expenses, food and lodging while ill, and informal care of any kind (Segel, 
2006b, Jo, 2014, Rice, 2000, Kirschstein, 2000, Hodgson and Meiners, 1982). 
The importance of catastrophic health expenditure 
Catastrophic health expenditure as a metric is usually expressed as the presence of direct costs 
exceeding some threshold level of household expenditure.  Some regard direct costs greater than 
10% of total household expenditure as likely to be catastrophic for the household, whereas others 
use a threshold of 40% of non-food expenditure. In either case, health expenditure above this level 
is likely to force household members to reduce consumption of other essentials and potentially 
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coping mechanisms such as depletion of savings, sale of assets, or incurment of debt (Russell, 
2004, Prescott and Pradhan, 1999, Ranson, 2002). In addition, the financial risk of disease may 
accrue over time pushing a household deeper into poverty. This can occur even if direct costs are 
low, when the associated coping mechanisms involve other household members, e.g. labour 
substitution, productivity loss due to caregiving, and loss of income if the patient is the major bread 
winner of the household. This phenomenon is likely to play a factor in diseases of poverty like 
RHD where the government provides care basically for free, but there are other costs to households 
resulting from reduced educational attainment and employment. Poor households affected by RHD 
are probably held back by direct nonmedical and indirect costs including lack of access to social 
grand from the government (WHO, 2001). 
Indirect costs  
Indirect costs are always opportunity costs and include household productivity effects such as lost 
wages (or equivalent value of time) for patient and caregivers (Segel, 2006b, Russell, 2004). In 
COI studies, indirect costs represent the other side of costs, reflecting productivity loss from 
premature mortality and disability that are borne by patients and their families. The commonly 
used method to calculate indirect cost in cost of illness study is human capital approach (Wang et 
al., 2016). Among children and working-age adults, illness carries a cost due to “absenteeism” and 
“presenteeism” in the education and labour sectors. There are three ways of measuring indirect 
costs: the human capital approach, the friction cost method, and the willingness to pay method 
(Segel, 2006b, Drummond and Jefferson, 1996).  
Household Coping Strategies 
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Coping strategies can be defined as actions that aim to manage the costs of an event or process 
(e.g., illness) that threatens the welfare of one or more members of the household  (Russell, 2004). 
Coping strategies seek to sustain the economic viability and sustainability of the household 
(Russell, 2004, Sauerborn et al., 1996). Coping strategies can be in response to direct costs (e.g., 
borrowing from friends or relatives, or taking out formal loans) or indirect costs (e.g., intra-
household labour substitution). They can vary from cost prevention strategies (e.g., ignoring 
illness, non-treatment) to cost management strategies (e.g., borrowing, selling assets, or labour 
substitution). Rural households are more likely to use savings than sell assets, and credit markets  
are more accessible to urban households than to rural ones  (Russell, 2004, Sparrow et al., 2014).  
Other coping strategies that have been documented include changing productive activities, 
receiving in-kind help from friends and relatives, delaying payment to private health care 
providers, being exempted from medical fees, receiving financial support from children, receiving 
reimbursement from medical schemes, and receiving social relief (Ding et al., 2008, Qiu and Li, 
2008). Different diseases probably result in different coping mechanisms based on the severity of 
such illness, whether it is acute or chronic, and whether it is recurrent/relapsing or progressive 
(leading to steadily deteriorating health) (Ding et al., 2008). 
1.3. Methods 
The primary aim of this study is to develop and pilot individual and household cost data collection 
instruments that can measure the household economic impact of RHD.   
This study is very relevant to the global NCD research and policy agenda. RHD is a neglected 
disease of poverty that disproportionately affects children and working-age adults, in whom the 
economic impact of the condition is likely to be very high. Since there has been no research on the 
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household economic impact of RHD in African countries, this study will be a novel contribution 
to the literature and will inform policy and advocacy efforts. 
Data Source: the REMEDY study 
The Global Rheumatic Heart Disease Registry (The REMEDY study) is a multi-center, 
international, hospital-based prospective registry of patients with RHD. It is designed as a cohort 
study to document the disease characteristics and outcomes of individuals with RHD across many 
countries (Karthikeyan et al., 2012, Zühlke et al., 2015a). REMEDY Patients were enrolled across 
25 sites in 12 African countries as well as in, Yemen and India; enrolment was based on a primary 
diagnosis of symptomatic RHD based on clinical and echocardiographic criteria (Zühlke et al., 
2015a, Fever, 2004).  
Study population and sampling approach 
The study population will be a series of households affected RHD. These households will include 
patients (index cases) their caregivers and other household members. The target sample size will 
focus on recruiting participant from total of 500 patients in REMEDY study conducted in Groote 
Schuur Hospital (GSH) and Red Cross Children’s Hospital (RXH) in Cape Town. These two sites 
have about 500 participants in total. We will sample index cases from the REMEDY database 
using a stratified approach -- The REMEDY study includes about 500 participants. This study is 
cost intensive and could not stretch further financially, so the sample size was set at 100. We will 
randomly sample 100 participants as follows. The REMEDY investigators will randomly sample 
100 names from their database and provide us with contact details. We will work with a research 
nurse on REMEDY to call these individuals and invite them to participate in this “sub study” of 
REMEDY.  Names and contact details of individuals who refuse to participate will be destroyed. 
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Once we have 100 participants, we will keep their names and contact details in a secure location. 
All study materials, including consent forms and data collection instruments, will be kept in a 
secure location as well. This sample size has been chosen to balance feasibility and precision and 
to align with a parallel study of the cost of RHD to the health system that aims to sample medical 
records from 100 REMEDY participants. Assuming an average total cost of US$ 100 per patient 
per year with a variance of US$ 900 (i.e., uncertainty range of about +/- 30% of the mean), a 
sample size of 100 will provide a 5% margin of error. 
Inclusion criteria   
The inclusion criteria in this study are: 
1. REMEDY participants who are available/ reachable by mobile and willing to take part in 
the study will be included.  
2. Heads of household or other members designated as decision-makers will be included 
Exclusion criteria   
      1.    Individuals under age 18 
Data collection instruments and procedures 
Instruments used 
Two sets of questionnaires are developed (Individual and Household questionnaire). The 
individual question consists of all the necessary variables: demographic, income and sources of 
income, cost of illness variable (direct medical cost and direct non-medical cost), indirect cost and 
coping mechanism. The cost section focusses on the outpatient and inpatient for hospitalization. 
The household questionnaire also has demographic, income etc.  The questionnaires developed: 
(1) is directed to the index participant (REMEDY participant) and (2) is directed to the household 
representative. The questionnaires will be completed by data collection experts hired to conduct 
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the research. (The questionnaire is not self-completed.) Both questionnaires do attempt to capture 
the impact of illness on caregivers; however, we will only seek information on caregivers from the 
index participant and household representative since we cannot feasibly interview all individuals 
in the household who may provide care for the patient with RHD. The questionnaires will first be 
piloted to ensure that questions are simple and easy to understand by the respondents. Following 
the interview, respondents will be asked about the clarity of the questionnaire and their 
understanding, comprehension of the questionnaire from the translator point of view. Several 
consent forms will be provided in the household questionnaire, consent will be taken from the HH 
head/respondent including other HH members (spouse, parent, children etc.) that may participate 
during the data collection process.  Variables from NIDS, SAGE and EQ-5D questionnaires 
adopted in the design of both the individual and household questionnaire.  
           Eq-5d score 
A standardized instrument which was developed by the EuroQol Group to measure health related 
quality of life, with descriptive system which has 5 dimensions mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. The EQ VAS records the patient’s self-rated health on a 
vertical visual analogue scale. EQ-5D is not only useable in public health but wide range of health 
treatment and condition. It is always used as quantitative measure of health outcome that reflects 
the patient’s own judgement. The scores can be presented as a health profile or can be converted 





The recruitment process will be for the index case, the REMEDY participant. This person will 
undergo the individual questionnaire (Appendix 6.4). In addition, we are clarifying that we will 
ask one household member to serve as a representative to answer the household questionnaire 
(Appendix 6.3). The preferred respondent will be the head of household or their spouse, but we 
will accept participation of whatever household member can reliably answer on behalf of the 
household (i.e., reliably discuss household finances and decision-making). If such a person is not 
available, we will ask the index participant to complete the household questionnaire and note this 
in the data set. We clarify that no other individuals in the household will participate in the survey.  








out-of-pocket payments on consultations, 
medications, tests, 





Time cost, accommodation, food and 
transportation  




Productivity loss, income reduction, loss of 
job 






Loan, assets sold and caregiver productivity 
loss 
Individual patient, caregiver and 
household 
  
Data analysis and management  
The main outcomes for the study will be;  
1. The average yearly cost of RHD to the household, including the breakdown between direct 
and indirect costs 
2. The prevalence of coping strategies (intra-household labor substitution, borrowing, selling 
assets, etc.)  
3. Other aspects of RHD that influence household economic dynamics 
The interview guide will be pre-coded for ease of data entry. Data will be transferred from data 
collection forms into an electronic database (Microsoft Access or other) and cleaned. There will 
be double entry of data to cross-check any errors during the data collection and entry processes. 
The data will be described using descriptive statistics: means and standard deviation for normally 
distributed continuous variables and medians and interquartile range for non-normally distributed 
continuous variables. Categorical variables will be summarized using proportions and differences 
in households will be compared using chi-squared tests or Fisher’s exact tests if one or more cells 
have an expected frequency less than five. Everything will be done at 95% level of confidence. 
Continuous variables will be assessed for normality using histograms. Multiple linear regression 
will be used to identify predictors of increased cost (e.g., severity of disease, patient age, household 
dependency ratio, etc.). Multiple logistic regression will be used to identify predictors of coping 
strategies (like the above factors). Qualitative findings from the open-ended questionnaire will be 
synthesized using thematic analysis. 
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Reporting of results 
A copy of the results of this study will be submitted to the university database. The work will then 
be published in a peer reviewed journal and in a written policy brief. 
Validity and Reliability of Measuring Instruments 
The instruments will be piloted on the first few patients to check for clarity of the questions and 
reproducibility of answers. Any revisions to the instruments will be submitted to HREC for 
approval. The interview setting, and conduct will be comparable to avoid any differing in 
responses. Fixed and closed rooms will be used to avoid noise and other distractions to ensure 
privacy and confidentiality of the participants.  
Standardizing the questionnaire and other interview guidelines will ensure that both questionnaires 
(individual patient and Household) are reliably designed. The data collector will be a fluent speaker 
of the patient’s preferred language and will ensure that the questionnaire is administered in the 
same way to each respondent/research participant. In addition, constant supervision will be 
provided by the principal investigator. 
Pilot Survey 
The study will be pretested before the main data collection process. The pretesting of the 
questionnaire helps in the planning for logistics and appraising the adequacy of the recruited data 
collectors to conduct the field work (Joubert et al., 2007). One of the main method of assessing the 
reliability of a study’s instruments is by comparing the responses given by the respondent during 
the pre-tests (Taylor and Weisberg, 1989). The pilot study will be pretested in few households to 
check for potential issues of consistency, sensitivity, format, wording and clarity of questions, 
instructions and any other factors that might have a negative bearing on data collection and analysis 
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process. It is assumed that pretesting the questionnaire on few households will be sufficient for 
validation. After pretesting, necessary adjustments and refinements to the instruments will be made 
before commencing main data collection.  
Ethical and legal consideration  
Potential Risk 
This study will entail minimal risk to participants. Potential risks and discomforts will be limited 
to psychological distress related to discussing illness or personal economic or financial 
circumstances. There will be no direct benefits to the research participants, but having the 
opportunity to ‘tell their stories’ and to have someone to listen to them may be therapeutic and 
satisfying for them. Since the findings of the study will be published, it may strengthen the health 
system response to RHD including better financing arrangements and more equitable services.  
Information sheet and informed consent forms 
Participation in the study will be voluntary. An information and consent document containing the 
overview and objectives of the study will be read out to all participants prior to any interview. 
Upon understanding the study information, individuals who wish to volunteer to participate in the 
study will be required to acknowledge their participation by signing the statement of consent on 
the informed consent document.  
Confidentiality 
To maintain confidentiality, the data collection instruments will use unique identifiers so that the 
identity of the participants remains anonymous. A link file containing unique identifiers will be 
constructed based on the household roster and will be stored in a secure location separate from the 
data collection instruments. All electronic data will be stored in the researcher's personal computer 
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and will only be accessible to the researcher, supervisors and other members of the larger team. 
Data will be disposed after publication of the study findings. 
Informed consent (or assent) will be obtained from all participants (household members) prior to 
data collection. Consent will be obtained in the participants’ language of preference using a 
translator if necessary. Ethical approval will be sought from the Human Research Ethics 
Committee (HREC) at the University of Cape Town. 
Proposed time schedule or duration 
The project will be spread across Eight-month period from conception to final report. The Gantt 
chart below shows the summary of key milestones to be accomplished with the final report and 
policy brief being submitted in early October 2017. 
1.4.Ethical Issue 
A field worker will be hired through the Health Economics Unit who is trained in research practices 
and ethics and is fluent in all local languages and understands data collection documents to be able 
to properly interpret the details of study to all respondents before their participation. Interaction 
will be made between the principal investigator and the field worker before the commencement of 
the data collection process on how to interact with the participants.  Issues that will be clarified 
included the following: 
• The purpose of the study. 
• That participation would be on a voluntary basis. 
• That the participant is free to withdraw from the study at any time. 
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• To give information about the use of data collection instruments and duration of each 
interview, Assurance of confidentiality via coded identity and other means. 
• To discuss potential benefits of the study outcomes. 
• To obtain informed consent prior to the commencement of the interview. 
• The main emphasis will be placed on the points below: - Consent form 
All participants / respondent will be given a copy consent forms to read for themselves, which they 
were free to accept or refuse to sign. There will be no undue influence on the prospective 
participants. The subjects will be notified of their right to refuse or withdraw from the study if they 
wished. Participants will also be informed of their right to ask any questions and stop the study 
process at any point in time for clarification or better understanding of the question. Consent forms 
is developed in English but the data collectors will communicate to them in their native languages. 
The consent form will be given to respondents to sign before the commencement of the data 
collection process. (See appendix no.6) Finally, the field worker will ask the participants to 
summarize the information on the consent form in their own words to check for understanding.  
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1.6.  Protocol Appendices 
 Appendices A: Information and consent Form 
Research Study: The Household Burden of Rheumatic Heart (RHD) Disease in South Africa 
E53, Room 46, Old main Building, Groote Schuur Hospital Observatory. 
Investigators 
Oyebamiji Oyeleke; Master of Public Health (Health Economics) University of Cape Town, Dr. 
Olufunke Alaba Health Economics Unit, Department of Public Health and Family Medicine 
University of Cape Town, Dr. David A. Watkins Department of Medicine, University of Cape 




We are asking you to be in a research study. The purpose of this consent form is to give you the 
information you will need to help you decide whether to be in the study. Please read the form 
carefully. You may ask questions about the purpose of the research, what we would ask you to do, 
the possible risks and benefits, your rights as a volunteer, and anything else about the research or 
this form that is not clear. When all your questions have been answered, you can decide if you 
want to be in the study or not. This process is called “informed consent.” 
Purpose of this study 
You are being asked to participate in a research study of; The Household Burden of Rheumatic 
Heart Disease (RHD) In South Africa. The purpose of the study is to investigate the economic 
consequences of RHD may impose on household budget and household activities. You are selected 
as a possible participant in this study because you are part of the REMEDY study that was done. 
You are one of the 100 participants that have been selected to participate in the research. In total, 
100 Participant who are part of the REMEDY registry study conducted in Groote Schuur Hospital 
and Red Cross War Memorial Children Hospital will be selected to participate in the research.  
Study procedures 
You can be in this study because you are taking part in the REMEDY study.  
We will contact you REMEDY participants by calling each and every participant on phone by 
(research nurse), to Set up time and place to conduct survey (preferably at the patient’s residence); 
note to the patient the need for another household representative to be present at that time (research 
nurse), meeting the patient and household representative at the specified place at time (principal 
investigator and field worker), obtain informed consent from participants (field worker), conduct 
individual survey (field worker), to review individual survey for completeness and accuracy (field 
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worker), thank participants for their time (field worker and principal investigator), store all hard 
copies of study materials in secure location (principal investigator), at earliest convenience, 
provide participants with copies of consent forms (research nurse) and  finally, extract data from 
study materials into electronic database (principal investigator or other qualified team member). 
Potential Risk and discomfort  
This study will entail minimal risk to participants. Potential risks and discomforts will be limited 
to psychological distress related to discussing illness or personal economic or financial 
circumstances. There will be no direct benefits to the research participants but having the 
opportunity to ‘tell their stories’ and to have someone to listen to them may be therapeutic and 
satisfying for them. Since the findings of the study will be published, it may strengthen the health 
system response to RHD including better financing arrangements and more equitable services.  
Other information 
Taking part in this study is voluntary. You can stop at any time. Your choice about taking part in 
this study will not affect your future medical care.  
The researchers have procedures to protect the confidentiality of study records. We will keep track 
of your study information by using the study code that you have been assigned as a participant of 
the Household burden of Rheumatic Heart Disease (RHD) in South Africa. All electronic data will 
be stored in the researcher's personal computer and will only be accessible to the researcher, 
supervisors and other members of the larger team. Data will be disposed after publication of the 
study findings. 
Benefits and/or compensation 
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There are no direct benefits to you participating in this study. This project aims to understand the 
burden of RHD and the impact on households. This information will be valuable to a range of 
different people, including policies makers who can use this information in decision-making. We 
cannot and do not guarantee or promise that you will receive any benefits from this study. 
Subject’s statement 
This study has been explained to me. I have read this consent form in full or it 
has been read to me in the presence of a witness. I volunteer to take part in this research.  I have 
had a chance to ask questions.  If I have questions later about the research I can ask one of the 
investigators listed above at the contact number addressed above.  If I have questions about my 
rights as a research subject, I can call Ms Lamees Emjedi with the Human Research Ethics 
Committee at 021 406 6338. I will receive a copy of this consent form. 
______________________  ____________________   ______________ 
Subject name                       Subject signature              Date 
______________________  ____________________    ______________ 
Witness name                      Witness signature             Date 
______________________    ____________________    ______________ 
Investigator name                 Investigator signature        Date 
Appendix :B Data collection procedures 
The following is an outline of procedures that will help you get started on the Appendix: 
1. Contact REMEDY participant by phone (research nurse) 
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2. Set up time and place to conduct survey (preferably at the patient’s residence); note to the 
patient the need for another household representative to be present at that time (research 
nurse) 
3. Meet the patient and household representative at the specified place at time (principal 
investigator and field worker) 
4. Obtain informed consent from participants (field worker) 
5. Conduct individual survey (field worker) 
6. Review individual survey for completeness and accuracy (field worker) 
7. Conduct household individual survey (field worker) 
8. Review household individual survey for completeness and accuracy (field worker) 
9. Thank participants for their time (field worker and principal investigator) 
10. Store all hard copies of study materials in secure location (principal investigator) 
11. At earliest convenience, provide participants with copies of consent forms (research nurse) 
Extract data from study materials into electronic database (principal investigator or another 
qualified team member) 
 
 
2. LITERATURE REVIEW 
 
2.1. Introduction 
This section aims to provide a detailed theoretical, methodological and empirical review of 
literatures on chronic diseases, cost of illness (COI), economic burden at household level in Africa 
especially South Africa. The Cost of illness (COI) at household level examines the direct and 
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indirect cost of resources used for the treatment of an illness/disease, coping strategies implored 
by the households and the impoverishment impact of the health expenses. 
2.2. Background 
Non-communicable diseases (NCDs) in low and middle-income countries account for about 77% 
of mortality, 85% of total burden of disease and several economic losses due to the reduction in 
productivity (WHO, 2005, Tagoe, 2012, Finkelstein et al., 2014). In 2008, about 36 million people 
died from NCDs including cancer (21%), cardiovascular diseases (48%), chronic respiratory 
diseases (12%) and diabetes (3%); chronic obstructive pulmonary disorder (COPD) accounted for 
about 4% of global burden of disease and about 8.3% of chronic disease (WHO, 2014, Health, 
2013, Nundy and Han, 2012, Finkelstein et al., 2014, Alwan, 2011, Cruz, 2007, Yoo et al., 2016). 
Non-communicable diseases account for 44.1% and 44.7% of deaths among males and females 
respectively that are below 70 years of age in developing countries (Siegel et al., 2011). Findings 
report that the range of hypertension prevalence  is between  14% -  40% among those between 35 
to 65 years of age and  about only 27% controls their blood pressure (Ordúñez et al., 2001).  
 
2.3. Burden of chronic disease in South Africa 
Non-communicable diseases also known as chronic diseases have increased in the last 15 years 
propelled by different risk factors such as obesity, physical inactivity, and diabetes (Heerden et 
al., 2017, Marquez and Farrington, 2013) in the rural and the urban area of South Africa. In 
2004, 28% of total burden of disease was caused by non-communicable diseases as measured by 
Disability Adjusted Life (DALY) (Mayosi et al., 2009). Global burden of disease estimates 
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performed in 2010 calculating the number of individuals living with Rheumatic heart disease 
(RHD), an NCD was at least 34.2 million, with 10.1 million disability-adjusted life years lost (de 
Dassel et al., 2015).  
In the few epidemiological studies conducted in South Africa, most of the recorded antenatal 
mortality were related to RHD with heart failure as the most common presentation (Sliwa et al., 
2014, Pillay, 2008). Furthermore, a recent systematic review on the incidence, prevalence, and 
outcomes of RHD in South Africa in the past 20 years reported a prevalence of 20.2 cases of 
asymptomatic RHD per 1,000 school children (Zühlke et al., 2014, Zühlke et al., 2015). 
2.4. Economic Burden 
Cardiovascular diseases (CVD), diabetes and other related NCDs are not only a public health issue 
but also an economic problem in the 21st century (Zimmet et al., 2001) with huge negative impact 
on the economic activities of people and national health, leading to premature morbidity and 
mortality associated to NCDs  in low and middle income countries with serious financial burden 
as a result of cost incurred due to prevention and treatment across different households (HH) 
(Zimmet et al., 2001, Yusuf et al., 2001, Gaziano, 2008).  People with most cases of type 2 diabetes 
in 2010 rose from 150-220 million, and was projected to rise to 300 million in 2025  (Zimmet et 
al., 2001, King et al., 1998).   
 Cardiovascular disease recorded  high rate of death in women and  men,  and causes the poor to 
become the most vulnerable in both the developed and developing countries (Yusuf et al., 2001).  
Africa and Asia are experiencing the incidence of RHD at a high level, recording an estimate of 
less than one to more than  15 per 1000 per year which  led to about 30% of CVD inpatient 
admission (Mendez and Cowie, 2001). Whereas, CVD as the second leading cause of death was 
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projected to be more than double in the 1990 and 2020 after HIV/AIDS (Gaziano, 2008). The cost 
of CVD differs across countries in sub-Saharan Africa which South Africa happens to be the only 
one to have been estimated.  
The cost of cardiovascular diseases in the United States is on the order of 2% of the gross domestic 
product (Heart and stroke statistics, 2002).  In Africa, CVDs as a percentage of GDP is  6.3%, with 
Republic of Congo to be 2.5% and Malawi recorded one of the highest GDP of  12.9%  (Gaziano, 
2008). Furthermore, a study on Economic burden and the cost-effectiveness of treatment of 
cardiovascular diseases in Africa explains that government, private sectors and individuals are the 
ones that bears the financial cost burden impose at the HH due to CVD. The cost burden are 
associated to indirect cost i.e. productivity loss due to workers affected with valvular heart disease 
(Gaziano, 2008). 
A study reported in Canada showed that 21% of the cost of illness are attributable to cardiovascular 
diseases with a total of US$ 12 billion annually (Health in the Americas, 2002). Since there are 
severe cases of type 2 diabetes, directing funding on NCDs could be cost intensive, looking at the 
impact of premature morbidity and mortality that could overshoot healthcare budget of developing 
countries (Zimmet et al., 2001). Therefore, the annual cost of diabetes in Latin America and the 
Caribbean was predicted to be at US$65.2 billion (2000) (Stephens and Joubert, 2001). The highest 
costs are attributed to permanent disabilities due to complications from diabetes (Barcelo et al, 
2003).  Kang et al., 2016 demonstrated that patients are frequently diagnosed with multiple 
respiratory disorders and the mean annual cost for patients with a respiratory disease was 
US$8,853 with lost productivity being the main contributor to overall costs (Kang et al., 2016). 
This was consistent with other studies which show that patients with concomitant respiratory 
disease have greater morbidity and high health care resource use  (Bousquet et al., 2005).  
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2.4.1. Burden of Rheumatic Heart Disease  
An important but neglected NCD is rheumatic fever and rheumatic heart disease (ARF/RHD) the 
leading causes of heart failure (Watkins et al., 2016). Rheumatic heart disease (RHD) has become 
major cause of cardiovascular disease among children and working-age adults in LMICs. RHD 
results from recurrent episodes of acute rheumatic fever (ARF), a delayed complication of sore 
throat due to group A streptococcal infection, which mostly affects children aged 5-14 years (Sliwa 
et al., 2010, Otto, 2004, Cilliers, 2014).   
There is paucity of data regarding the prevalence and incidence of GAS pharyngitis in South Africa 
Incidence rates of ARF are poorly documented in most low and middle-income countries. 
However, (Van Zyl et al., 1981) reported an overall prevalence of 33.2% with a significant 
difference between rates for Blacks (45%) and Whites (23.2%) in a study conducted in Pretoria on 
232 patients (Van Zyl et al., 1981). In another study conducted in a Black community in 
Bloemfontein, 42% of the population has Group A Streptococcus GAS positive result was obtained 
(Irlam et al., 2013). In the few epidemiological studies conducted in South Africa, most of the 
recorded antenatal mortality were related to RHD with heart failure as the most common 
presentation (Soma-Pillay et al., 2008, Sliwa et al., 2014). Furthermore, a recent systematic review 
of the incidence, prevalence, and outcomes of RHD in South Africa in the past 20 years reported 
a prevalence of 20.2 cases of asymptomatic RHD per 1,000 school children (Zühlke et al., 2014, 
Zühlke et al., 2015b).  
Table 1: Characteristics of Articles selected for literature review 
Authors Subject of study location Methodology Results 
47 
 
Foster et al., 2015 Tuberculosis South Africa Estimated the out-of-pocket 
costs incurred by individuals, 
examined reliance on social 
networks to mediate a 
catastrophic fiscal impact on 
the household 
Patients incurred the greatest share of TB 
episode costs (41%) prior to starting 
treatment, with the largest portion of these 
costs being due to income loss. Poorer 
patients incurred higher direct costs during 
treatment than those who were less poor. 
Indirect costs accounted for 52% of total 
episode cost. 




Adopted a societal perspective 
by incorporating the impact on 
the individual, the household, 
and the health and economic 
sectors. 
In both countries, there was a paucity of 
systematic efforts to measure the economic 
and social impact of CVDs and diabetes. 






Indonesia Performed econometric 
analyses based on four waves 
of the Indonesian Family Life 
Survey (IFLS). The average 
daily labour rate was 
equivalent in value to the lost 
days of primary activity 
Heart problems exerted the greatest 
economic burden on households, costing 
Int$1.56 billion in OOP and indirect burden 
in 2010 followed by hypertension (Int$1.36 
billion), diabetes (Int$0.81billion) and 
stroke (Int$0.29 billion). 









Reviewed studies that 
measured the economic costs 
and consequences of illness for 
patients and their families, 
focusing on all illnesses, 
malaria, tuberculosis (TB), and 
HIV/AIDS. 
Direct and indirect costs of illness for 
malaria were less than 10% of the 
household income, but still significant when 
combined with the costs of other illnesses. 
The costs of TB and HIV/AIDS were 
catastrophic for households (more than 10% 
of the income).  
Le et al., 2012 Hypertension China Prevalence-based cost-of-
illness method was used to 
estimate the economic burden 
of hypertension. 
On average, males had higher overall 
direct, indirect and intangible costs of 
hypertension than females. Both indirect 
and intangible costs decreased with age, 
whereas direct costs increased with age. 
The incidence of household catastrophic 
health payment and household 
impoverishment because of hypertension 
was 8.9% and 4.1%, respectively. 
Le et al., 2015 Coronary heart 
disease  
China Prevalence based cost-of-
illness approach was used to 
estimate the economic burden 
of CHD. Multilevel linear 
regression was used to model 
the variation in costs of CHD. 
Males were more likely to have a higher 
economic burden of CHD than females. A 
positive association was found between the 
individual's level of education and the 
economic burden of CHD. Residence in a 
higher-income community was associated 
with higher costs related to CHD. 
Min Hu, PhD 
Candidate,Wen Chen, 







The rate of outpatient visits 
and average cost per visit 
reported by the patients was 
used to measure the outpatient 
expenditure per patient while 
the inpatient cost was 
calculated through annual rate 
of hospitalization and average 
expenditure for different types 
of hospitals. The Human 
Capital Approach was 
employed to measure the work 
loss cost due to productivity. 
CHB-related diseases impose a substantial 
economic burden on patients, families, and 
the society in China urban areas.  
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Direct medical costs included 
total outpatient, inpatient, and 
self-treatment expenditures; 
direct nonmedical costs 
included spending on 
nutritional supplements, 
transportation, and nursing per 
patient 
For patients with or without health 
insurance, direct out-of-pocket cost of all 
HBV-related diseases except acute 
hepatitis B exceeded 40.00% of the 
patient’s disposable household income, 
making it a catastrophic expenditure for the 
household. 
Wang et al., 2016 Chronic non-
communicable 
diseases 
Malawi A cost-of-illness method was 
applied to estimate the 
economic burden of CNCDs. 
Indicators of catastrophic 
spending and impoverishment 
were used to estimate the 
economic burden imposed by 
CNCDs on households. 
Using a threshold of 10 % of household 
non-food expenditure, 21.3 % of all 
households with at least one household 
member reporting a CNCD and seeking 
care for such a condition incurred 
catastrophic spending due to CNCDs. The 
poorest households were more likely to 
incur catastrophic spending due to CNCDs. 
An additional 1.7 % of households 
reporting a CNCD fell under the 
international poverty line once considering 
direct costs due to CNCDs. 








India Costs, indirect and direct, that 
contributed to treatment for 
each of the four respiratory 
diseases were calculated. 
Asthma was the most frequent primary 
diagnosis followed by AR, COPD, and 
rhinosinusitis. A total of 335 (33.5%) 
patients were diagnosed with combinations 
of the four respiratory diseases; the most 
frequently diagnosed combinations were 
asthma/AR and rhinosinusitis/AR. Cough 
or coughing up sputum was the primary 
reason for the current visit by patients 
diagnosed with asthma and COPD while 
AR patients reported a watery, runny nose, 
and sneezing; patients with rhinosinusitis 
primarily reported a coloured nasal 
discharge. The biggest cost component was 
productivity loss. 
Duraisamy et al., 2006 PLHA and 
households 
South India Multiple regression analysis 
was used to examine the 
determinants of direct costs. 
Other tests included One-way 
ANOVA (F-test), Mann-
Whitney U and the Kruskal-
Wallis test performed to test 
for statistically significant 
differences in the distributions 
and median. 
Direct costs and financial burden of care 
and support services increased with the 
stage of disease. The financial burden was 
disproportionately more on low-income 
households. 
Abegunde et al., 2007 Chronic diseases 23 countries Simple models were used to 
project future mortality and 
burden of disease trends 
Results showed that population growth and 
ageing will drive a substantial increase in 
the numbers of deaths from chronic disease 
globally, and particularly in low income 
and middle-income countries. 
Lee et al., 2016 Heart failure South Korea Subgroup analyses of the costs 
consisting of direct costs (i.e., 
medical and non-medical 
costs) and indirect costs (i.e., 
productivity loss cost due to 
morbidity and premature 
death) were conducted by age 
group, history of HF 
hospitalization, and type of 
A high percentage (68.5 %) of 
socioeconomic burden consisted of 
medical costs, caregiver’s cost, 
productivity loss costs due to premature 
death and morbidity, and transportation 
costs. The HF patients with prior 
hospitalization due to HF annually spent 
9.7 times more for National-Health-
Insurance-covered medical costs compared 
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universal health security 
program enrolled in 
to HF patients who were not previously 
hospitalized. 
Tagoe, 2012 Chronic diseases Ghana Measures of direct and indirect 
burden of chronic diseases at 
the household levels were 
constructed and assessed using 
bivariate and multivariate 
analyses. 
The relatively high direct cost of illness 
among households with person(s) living 
with NCDs and the associated high indirect 
burden of illness placed undue stress on 
households. 
Arredondo and Reyes 
2013 
Diabetes  Mexico The Box-Jenkins technique 
were used for developing 
probabilistic models for the 
estimation of epidemiological 
changes.  
In terms of health disparities, these data 
show clearly that there is a problem related 
to equity and poor health care accessibility 
in the different sectors of the Mexican 
population and according to the social 
group to which the patients with diabetes 
and their families belong to. 
Ogah et al., 2014 Heart Failure Abeokuta, 
Southwest 
Nigeria 
Outpatient and inpatient costs 
were computed including 
personnel, diagnostic and 
treatment resources used for 
their management over a 12-
month period. Indirect costs 
were also calculated. The 
annual cost per person was 
then calculated. 
The economic burden of HF in Nigeria was 
found to be particularly high considering, 
the relatively young age of affected cases, 
a minimum wage of 18,000 Naira 
($US120) per month and considerable 
component of out-of-pocket spending for 
those affected. 





USA Rising average age of the 
population and changing 
epidemiologic profile of the 
population are two main trends 
decomposed from the 
increasing prevalence of 
chronic disease in developing 
countries  
Variability in the prevalence of chronic 
disease was found both at the country level 
and within countries as differences in risk 
factors were observed. This upward trend 
was forecast to continue as epidemiologic 
profiles and age structures of developing 
countries further shift. 
Mahal et al., 2008 HIV/AIDS  Nigeria Propensity score matching was 
used for comparing HIV-
positive people with a control 
group with similar observed 
characteristics. 
HIV was associated with significantly 
increased morbidity, healthcare utilization, 
public health facility use, lost work time 
and family time devoted to care-giving. 
Sylvia C. Robles 2004 Chronic disease USA A public health response must 
bridge two approaches based 
on health promotion, 
addressing the determinants of 
risk factors and disease; and 
clinical cost-effective 
interventions and then 
integrate prevention and 
control of noncommunicable 
diseases in comprehensive 
programs. 
Application of this framework and the use 
of appropriate methods contributed to 
elucidate the overall system dynamics in 
various settings. 








Direct cost measures were 
based on exacerbations of 
COPD, contacts with 
healthcare professionals, and 
COPD medications. Indirect 
costs were calculated from 
work loss values using the 
Work Productivity and 
Total societal costs per patient varied 
widely but a consistent pattern across 
countries showed greater costs among 
those with increased burden of COPD 












Activity Impairment scale. 
Combined direct and indirect 
costs estimated the total 
societal costs per patient. 
disease) and a greater number of 
comorbidities. 
 
2.5.  Methods for Literature Review  
2.5.1. Search strategy  
Multifaceted Boolean searches of the Medline bibliographic database using the PubMed interface 
(National Library of Medicine) Google scholar and the Scopus search yielded nothing, so it was 
discarded. The literature search result from PubMed was used simultaneously with Google scholar.   
2.5.2.  Inclusion criteria 
• All published articles written in English from LMICs reporting on household economic 
impact/consequence of RHD chronic diseases with any kind of disease specifically. 
• Literature on alignment of the objective with the review  
• Study with adult of above 18 years of age was given preference   
• Study published in the last 15 years was mostly prioritized.  
• Quantitative studies or/and observational studies 
2.5.3. Exclusion criteria 
1. Randomized control trials, qualitative studies. 
• Any study from high income countries  

















Figure 1:  Flow chat diagram for the systematic review 








Full text article checked for eligibility 
(n=68) 
*Non-economic studies/communicable diseases (n=20) 
*No detailed methodology (n=17) 




 6 studies were found 
Empirical 
 
 14 studies were found 




2.6. Methodological Review 
One method to estimate the economic burden on households is cost of illness studies. 
Comparability of cost of illness studies can be very hard to conduct because of various definitions 
and methods they used to measure and quantify different cost in different literature. Studies explain 
COI approach attributed essentially to public health by seeing cost in the light of society being a 
healthy place to live and will have a corresponding effect on the reduction of medical treatment. 
COI studies have given a price on mortality and morbidity related to any risk factor to measure 
expenditure on health that can be saved if there is no case of illness compared to the general 
understanding of economic way of costing which have the tendency to exaggerate the true cost of 
all morbidity and mortality  associated with disease (Suhrcke et al., 2006b). In economic 
assessment of cost, there is always a comparative event between the present situation and the 
alternative situation that is contrary to the previous one. This study is viewed to be difficult to 
measure because dissimilar cost could be difficult to measure and methodology applied in COI 
studies does not address causality (Suhrcke et al., 2006b, Russell, 2004). Chronic diseases and risk 
factor cost are identified but do not specify that both were the reason why the cost happened. 
Several diseases have its peculiarity and differences in COI. In a study of costing of hypertension 
in rural China, their finding may have had a direct influence on the household due to several 
components of costs that was included for analysis in such study. Direct health care cost was 
majorly focused on, and indirect  and tangible cost were ignored (Le et al., 2012). Some other 
studies assessed direct medical cost that included all cost.  
2.6.1. Cost of RHD inpatient and outpatient visit 
2.6.1.1  Inpatient Cost  
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Inpatient cost generally refers to any medical service, direct cost transport, food, medications, 
consultation, accommodation and laboratory that is payed during admission into a hospital. Also, 
Indirect costs are expenses from the cessation or reduction of work productivity because of the 
morbidity and mortality associated with a given disease (Wolf and Colditz, 1998). Inpatient cost 
tends to be directed towards more serious diseases and trauma that need one or more days of 
overnight stay at a hospital   
2.6.1.2  Outpatient Cost 
Outpatient cost are direct and indirect cost incurred by patient during hospital visit without an 
overnight stay and can be aggregated as cost accrued for round trip per visit, food, medications, 
consultation and laboratory cost incurred by patient visit and productivity loss associated to 
productivity cost (value of time to seek care) which include household economic cost (Russell, 
2004, Drummond et al., 2015). 
2.7. Cost of ill-health 
The impact of disease varies, including physiological, social and economic effects, while some 
diseases are temporary and affect current earnings, others are long-term like RHD, NCDS and 
affects both current and future earning and the dynamics of the household. Several reviews have 
been conducted on the Cost of illness (COI) at household level that accesses the indirect and direct 
cost (i.e. opportunity cost of the resources used for the treatment of such disease) of a particular 
illness/disease (Segel, 2006b).   
2.7.1. Direct cost  
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Direct cost is typically defined as out of pocket payment incurred during the cause of seeking 
treatment for an illness episode. Russell, 2004, also categorize direct cost into main groups name; 
direct medical and direct non-medical costs. Direct cost can also be defined as cost incurred as a 
direct payment of medical cost associated with ill-health that  is borne by health care sector, and  
non-medical cost such as transport, special food cost incurred by the  patient and their HH/ families 
(Leardini et al., 2002, Duraisamy et al., 2006). 
2.7.1.1.  Direct medical cost  
Direct medical cost are household expenditure associated with treatment seeking attitude when ill 
(Russell, 2004).  Direct cost can further be categorised as medical related costs and non-medical 
costs (Hutchinson et al., 2006). Direct costs can also be called over-the-counter payment of 
medication, and consultation, prescription, diagnostic tests and hospital accommodation cost 
(Segel, 2006a) . 
2.7.1.2.  Direct non-medical Cost 
Direct non-medical cost are cost associated with transport, expenditure on special food and 
accommodation burn by patients to visit health providers, including household cost incurred  and 
cost of accompanying caregiver (Le et al., 2012, Wang et al., 2016). Also, direct non-medical cost 
stated by Russell 2004, are associated to special food supply and factors related to distance, 
availability and user fee policy. Direct non-medical costs include travel costs, costs of special food, 
caregivers' costs and costs of queuing at the health facility. 
2.7.2. Indirect Cost 
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Indirect cost is productivity cost (value of time to seek care) which include household economic 
cost and productivity effect (loss of wages) incurred by an individual and household/caregiver’s 
due to an illness episode (Segel, 2006b, Russell, 2004, Foster et al., 2015, Drummond et al., 2015, 
Barter et al., 2012).  Indirect cost model entails mortality and morbidity due to amount of income 
cost due to disability i.e. productivity loss due to absenteeism from work, caregiving to patient by 
household member associated with productivity loss due to morbidity  and premature death (Lee 
et al., 2016). Households experience the consequences of indirect cost such as children school 
dropout, reduction in food consumption and household  loss of wellbeing, inability to purchase 
household essentials so as to care or attend to the sick household member (Nugent et al., 2011). 
Indirect cost are very high in developing countries compared to direct cost on health in different 
households due to access in treatment of disease, but in developed countries direct costs are higher 
than indirect costs (Nugent et al., 2011).  WHO study discussed about chronic diseases and loss of 
economic output due to cardiovascular disease, stroke and diabetes of about $1.25 trillion in five 
developing countries in the year 2015. India had an estimation of about $336billion, Russian $300 
billion and China $557 billion (Nugent et al., 2011, Atlas, 2013).  Ghoshal et al., 2016 explained 
the impact of presenteeism over absenteeism, because it was more significant to lost productivity 
in the study conducted on economic cost of respiratory disease in India. To value the time loss 
from premature mortality and disability that is attributable to patients with chronic diseases in 
households, human capital approach is the most commonly used method. (Wang et al., 2016, 
Foster et al., 2015, Tarricone, 2006, Russell, 2004, Pritchard and Sculpher, 2000, Le et al., 2012). 
Studies around the COI in several low-income countries measured household indirect cost. A study 
in Sri Lanka described a very high direct cost for outpatient services in urban locations. A different 
scenario was reported in Burkina Faso where direct cost was recorded lower compared to high 
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indirect cost from the total cost (69%) and time loss by caregiver was equivalent to  loss by sick 
individual. (Russell, 2004).   
2.7.2.1.  Methodological approach to measure indirect cost 
Indirect cost can be measured in three major ways: the human capital approach (HCA), friction 
cost method (FCM), and willingness to pay (WTP) method (Segel, 2006b, Drummond and 
Jefferson, 1996, Segel, 2006a).  Research shows that in developing countries, HCA is mostly used 
in COI compared to the WTP and FCM (Wang et al., 2016, Wyss et al., 2001, Asenso-Okyere and 
Dzator, 1997, Sauerborn et al., 1991, Konradsen et al., 1997, Sawert et al., 1997, Segel, 2011).   
2.7.2.1.1. Human Capital Approach  
The most commonly used approach to calculate indirect cost is COI studies, and it estimates how 
human life is valued and quantifies such value produced by an individual lifetime as a function of 
the individual earnings (Wang et al., 2016). Explaining the method of valuing the productivity cost 
of HCA is the existing neoclassical economic theory; which state that profit maximizing 
firm/organization employ workers up to a point where their marginal contribution to production 
equals to their gross wage. Therefore, the human capital approach involves placing a monetary 
value on a human life; this approach can be used to estimate the value of an individual to his 
community according to the amount of income the individual earns  (Drummond et al., 2005). 
Also, HCA explains the process of giving value to potential productivity loss (de Santé, 2012).  
Therefore, Human capital approach (HCA) method can be used to calculate productivity loss costs 
due to morbidity and issue of premature deaths. 
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Advantages of HCA. HCA allows essential insight not available to the previous versions of 
neoclassical economics. Looking at Marxian and Ricardian traditional way of treating labour as a 
produced means of production who has its characteristics focus on the economic forces, HCA 
discards the assumption of homogenous labour and focus its attention on the differentiation of the 
labour force. Finally, it gathers simple social institutions such as schooling and family, subverted 
as basic cultural scene into main economic analysis (Bowles and Gintis, 1975).    
Disadvantages of HCA. The human capital approach (HCA) fails to recognize the value of pain 
and suffering that can be avoided through medical means as well as the value of leisure time. HCA 
does not consider the value an individual receives from the pleasure of life itself or the pleasure. 
Using the human capital approach, a person who is continually unemployed but still lives and 
breathes each day has effectively a zero value of life and may be also subject to market 
imperfections like race and other forms of discrimination (Bowles and Gintis, 1975). There is 
always causality between human and income which when combined, increases returns to 
investments in HC associated with imperfect credit market that leads to poverty trap.  Poor people 
are unable to put their investment in HC that could lead to low income and keep them 
impoverished. Looking at the human capital theory with the assumption of earning wage that 
reflect human productivity, It was argued that the effects of reduced worker productivity can be 
translated into low income earnings in the labour market (Sicherman, 1991).  
 Several studies across sub-Saharan African countries and other LMIC countries have used HCA 
method to calculate indirect cost. A study on heart failure in aging society in South Korea used 
this method to account for premature death due to loss of productivity because people who are sick 
and above the age of 65 are less productive and no longer contribute to the society (Lee et al., 
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2016). In Latin America, indirect cost of chronic diseases was calculated using HCA, monetary 
cost of diabetes related death. (Arredondo and Reyes, 2013). Another study conducted in Nigeria 
on heart failure estimated indirect cost by calculating average annual earnings on an individual 
patients  based of their work-related  group to get the average daily earnings (Ogah et al., 2014). 
The value of lost productivity because of illness can be measured by amount of forgone wages. 
Although HCA have been criticized by several economists in valuation of indirect cost, it’s still 
the most used approach in the estimation of direct cost compared to the rigorous willingness to 
pay and friction method. In a country where unemployment is very high, HCA does not give the 
value of productivity and does not reflect the true value of productivity because the assumption of 
perfect competition is unrealistic given that the empirical evidence explains that there is 
imperfection in  labour market  (Drummond, 2002). In this study, most of the patient are 
unemployed so, there is shortcoming in the use of HCA because they do not produce anything.  
2.7.2.1.2. Willingness to pay 
Willingness to pay approach (WTP) is used in the estimation of indirect cost of illness (Segel, 
2006b).  WTP method is employed in research to know how much an individual is willing to spend 
to avoid illness. It also explains that the value of lost production can be derived by analyzing 
related preference to risk factor. Research on the economic burden of hypertension in rural south-
west China shows that WTP are geared towards men and decline with age because men at working 
age are more productive and they are assumed to generate more income, but the older they get the 
less productive they are (Le et al., 2012). The more the household earn high income, the more they 
are willing to pay more to avoid ill health. Furthermore, WTP method describes value that 
households attach monetarily to a product to avoid illness or the value they attach if they are to 
accept the risk of illness. Wang et al., 2016 explained the shortfall of the study in Malawi that  the 
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method may induce individual/or respondent to estimate differently (over estimation or 
underestimation)  than what the actual estimate they would be willing to pay in a real life situation 
(Sawert et al., 1997).  
2.7.2.1.3. Friction cost method 
This approach helps in the reduction of overestimation of direct cost with the assumption that  there 
is likelihood of replacing any patients who missed work time due to prolonged  ill health, instead 
of keeping the placement unoccupied until the return of the sick patient or  alternatively the time 
taken to restore firm production to normal operating due to replacement or unavailability  (Foo et 
al., 2016, Koopmanschap et al., 1995). Segel, 2006a described FCM to estimate the COI from the 
understanding of firm and government where people work and earn monthly wages. This 
accounted for the alternative taken in other to keep a certain operation going while waiting for a 
substitute (Segel, 2006a).  
2.7.3. Drivers of Cost 
Drivers of cost are any factor that causes a change in the cost of an activity and bring out the 
consumption effect of firm resources. Also, they are associated with health expenditure with the 
underlying effect of sickness episode (Babad and Balachandran, 1993). Empirical studies hardly 
disaggregate total direct medical costs into the core cost drivers such as; user charges, consultation 
fees, diagnostic tests or drugs supply which account for total out of pocket payment from different 
households (Russell S, 2004).  
Household income and age are very important in the direct cost of illness (Russell, 2004, WHO, 
2009, Le et al., 2015).  
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In Sierra Leone, the poor household incurred over 50% of direct medical and non-medical cost on 
doctor’s visit as well as other Asian countries such as Thailand, China, India and in Sri Lanka. 
Mean direct cost burden for the illness was 6.5% out of the monthly income with median of about 
1.3% including doctors visit; transportation cost to health facilities could raise mean above the 
median (Russell, 2004, Fabricant et al., 1999, Wilkes et al., 1997, Pannarunothai and Mills, 1997, 
Mongkolsmai, 1993, Mishra et al., 1993). A South India study recorded that about 40% of the 
annual income of a patient living with Tuberculosis was channelled to healthcare (Kumarasamy et 
al., 2007).  Also, cost of illness study conducted on hypertensive patients in the rural area of 
Yunnan province in China in 2010 measured the total direct per unit cost for male as 542.1 and 
female 454.7 with overall total cost of illness of 53.4%. Direct costs of illness estimation are 
generally perceived to be a simple exercise on the surface, given that the cost components are 
easily quantified in monetary terms. The non-medical cost are accommodation cost, transport, food 
and all care seeking behaviour of the sick patient and their caregiver (Wang et al., 2016). 
Conceptually, to estimate the direct medical costs of treatment, one of three methods can be 
applied: The bottom-up approach, top down approach and econometric estimation (Segel, 2006b). 
The bottom-up approach in COI explains the input from the data that include the government, 
patient medical charts and interviews conducted on both the patients and medical staff. 
Furthermore, bottom-up approach estimates the direct medical costs e.g. cost of drugs supply by 
multiplying the unit cost by the used while the top-down approach estimates the COI by 
multiplying the average total health care spending by the proportion of the health services used by 
the type of diseases measured (Sam et al., 2009). The econometric approach gives the total 
estimated direct COI as there is a difference between the cost of treatment between  patient that 
are chronically ill and those who are  not.(Segel, 2006b). 
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2.7.3.1.  Health care expenditure as a proportion of household income-
impoverishment 
 The healthcare spending is seen as being catastrophic when there is a need for household to reduce 
their basic expenditure in other to cope with health care cost for a certain period of time (Xu et al., 
2003). Households tend to have rapid and immediate diminishing effects on household budget and 
household income. If the diminishing effects are sufficiently large, it is argued that the probability 
of household economic decline into poverty rises. Although there is little consensus as to the exact 
level of health expenditure that significantly diminishes economic welfare, it is widely accepted 
that direct cost expenditure exceeding a certain threshold of household income can impoverish the 
household.  Also, in a household headed by people with disabilities or chronic diseases, 
unemployed and especially people without health insurance are more likely to face financial 
hardship than other households without impediment (Chuma et al., 2007, Kaplan et al., 1996). A 
study conducted in 89 countries globally suggested that 150 million people suffers financial 
catastrophe yearly due to payment of health care services (Xu et al., 2007). Income spent on other 
household food and non-food expenditure is more reasonable compared to income spent on ill-
health of one or more of the HH member.  However, wealthy HH are less likely to incur high cost 
of healthcare  that will impoverish them no matter the threshold compared to poor household that 
is paying for their healthcare out of pocket (Su et al., 2006). Paying for medical fees, user charges, 
purchase of medicine, diagnostic test and charges on public care out of pocket by income earner 
in the household can be catastrophic and can deepen that household into poverty  (Kruk et al., 
2008, McIntyre et al., 2006)  
2.8. Coping Strategy 
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The review on coping strategy explain how households respond to the consequences of illness 
based on the differences in decision they take to tackle such illnesses and the magnitude or severity 
of the sickness by focusing on direct and indirect cost shouldered by the household (Russell, 2004, 
Masiiwa, 2013). Coping strategy is defined  as the decision household take to manage the costs 
incurred in a sickness episode that impends the welfare of one or more members of the household 
(Russell, 2004). Additionally, COI to households may be compounded for individual and 
household member without financial security. This financial security can be insurance to help the 
poor household from incurring catastrophic health care expenditure (Leive and Xu, 2008). When 
there is no health insurance for poor household in low income countries, people are forced to pay 
high OOP for health care. Household employs different methods of coping due to the severity of 
disease and majorly productivity loss due to ill health. Long term chronic diseases such as TB lead 
household members to quitting their job or have someone take their place while they treat 
themselves (Russell, 2004). Also, households adopt coping mechanisms due to economic 
consequence of ill health by sourcing for money to mitigate such economic shock of direct cost 
(e.g. borrowing) and indirect cost (intra household labour substitution) (Russell, 2004, Buvé et al., 
2002). The study carried out in India by (Duraisamy et al., 2006) reported about  67% of patient 
had to borrow, while 16% said they made use of their income savings. In order to cope with indirect 
and direct cost, households are compelled to result to cost prevention method (e.g., ignoring illness, 
non-treatment) and cost management strategies e.g., borrowing from their various social networks 
,selling assets, or labor substitution and  take loan  (Alamgir et al., 2010, Sauerborn et al., 1996). 
As highlighted in Foster et al., 2015 study, TB patients at chronic stage in South Africa depends 
on the household members and/or caregiver to borrow money for their care (Foster et al., 2015). 
2.9 Empirical Review: COI Studies from Household Perspective 
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Household experience on impoverishment resulting from the effect of medical cost have become 
a major challenge. This has brought the upsurge in research to estimate the household different 
cost of illnesses over the years (Hu et al., 2008, Damme et al., 2004). Economic cost of illness is 
said to be aggregate of direct costs ( transport round-trip cost incurred from hospital or any health 
facilities) and other medical/consultation cost,  indirect cost, intangible cost associated with 
emotional stress and physical pain experience due to illness (Segel, 2006b, Foster et al., 2015). 
Also, due to the burden of disease, household may incur direct medical costs related to the type of 
illness or direct non-medical costs incurred to other costs associated with falling ill but not 
necessarily related to the illness. Therefore, studies across cost of illness breakdown illness cost 
into direct and indirect medical cost associated to the whatsoever expenditure incurred by different 
households.  
Recently in developing countries, unhealthy behaviours that lead to chronic diseases are common 
among people of all income levels and such behaviours are increasingly more likely among lower-
income people in countries above a certain income threshold. However, there is a difference in the 
burden enforced by chronic diseases in rich versus poor countries, in that, more morbidity and 
mortality from chronic diseases occurs before age 60 in low- and middle-income countries than in 
high-income countries. This burden is attributed to personal lifestyle change, physical activity and 
poor diet (Nugent, 2008).   
Figure 2 below shows the household impact of chronic disease related NCDs in the poor LMIC 
2.9.1.  Cardiovascular disease 
Cardiovascular disease in African countries has become a major public health challenge. African 
studies examined cardiovascular and heart related disease recorded that there are little or no data 
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describing the economic impact in sub-Saharan African countries. In a cohort of about 239 cardiac 
problem conducted in Abeokuta Nigeria, the total inpatient care cost was 46% from the total health 
care expenditure (Ogah et al., 2014). Also, transport cost was recorded very high due to OOP 
payment from their monthly follow up visit. 
Another population based household health survey conducted in rural Malawi in 2012 shows the 
chronic cardiovascular disease (CCVD) was recorded to have borne higher direct, indirect and 
total cost than other comorbidities (Wang et al., 2016). CCVD was recorded higher for mean 
monthly cost of about 74% of medical cost. More of this indication is associated to the record 
articulated  with global indices of NCD (Wang et al., 2016, Bloom, 2011).  Furthermore, in a multi 
country study conducted on cardiovascular mortality in 2001,sub-Saharan African countries 
recorded 30% of 95% uncertainty interval compared to the high income countries including the 
Asian countries (Abegunde et al., 2007, Mathers et al., 2006). 
2.9.2 Other non-communicable diseases in Africa 
Other non-communicable diseases are recorded across studies in low income countries, but Africa 
is yet to explored in full the research on NCDs at present. However, the impact of other NCDs 
(CVD, Diabetes, cancer etc) are very high with the increase in infectious diseases (HIV/AIDS) 
and TB that is about reaching epidemic stage stated by the World Health Report 2001.  The high 
impact of NCDs is wide spreading across Africa with Age-specific death highest in South Africa, 
Nigeria and Egypt (Abegunde et al., 2007). Study shows in Malawi that people incur direct cost 
on the treatment care of diseases like cervical cancer (cervical and breast), heart failure, diabetes, 
hypertension despite the free treatment plan which could not offer adequate financial protection 
against CNCDs related cost (Wang et al., 2016). HH suffer from the impact of NCDs due to long 
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term effect. In Ethiopia 2006, projection was made in achieving the global goal of adding 2% 
annual reduction in chronic disease related mortality estimated losses due to diabetes, stroke 
coronary heart disease ranges from 20-30 million US dollars and likely double if there is no 
prevention till the year 2015.  This may have very high negative economic impact on African 
countries. 
Conceptual framework 
The evolving experience of poverty at household level in low middle-income countries is described 
in Figure 2. People in LMICs faces diverse types of modifiable risk factors/ unhealthy behavior  
such as (physical inactivity, tobacco use and harmful use of alcohol) which leads to loss of income 
in the household (Heerden et al., 2017, Marquez and Farrington, 2013). Several LMICs countries 
suffers health related losses due to NCDs, which accounted for 90% of global burden of disease 
and recorded 12% of global health spending which in turn reduces access to effective and equitable 




Figure 2: Adapted from: (Aikins and Agyemang, 2015) 
2.10. Conclusion  
Burden of chronic diseases in Africa have become a public health issue and need urgent attention. 
Chronic diseases (CDs) have been seen to not only be a health issue but also an economic problem 
that affects both the developed and developing nations. There is numerous household cost of illness 
studies that investigate the economic consequences of CVD, malaria, diabetes, HIV and 
tuberculosis. Furthermore, household cost of illness is estimated using direct and indirect cost. The 
estimated household economic impact of RHD is very relevant to the global NCD research and 
policy agenda, knowing that RHD is a neglected disease of poverty that disproportionately affects 
children and working-age adults in LMICs where the economic impact of the condition is very 
high and that when faced with the economic consequences of illness at HH level, they adopted 
coping strategies (borrowing from social network, sold property etc.).  Since there are no prior 
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research on the household economic impact of RHD in African countries, and thereby limited in 
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The household economic impact of Rheumatic Heart Disease (RHD) in South 
Africa 
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Abstract 
Background: Rheumatic Heart Disease (RHD) is an incurable and often costly condition. It is an 
important cause of cardiovascular death and disability in South Africa that predominately affects 
poor and socially vulnerable populations. Due to the paucity of data describing its economic 
impact, we conducted a survey to investigate the economic consequences of RHD among South 
African households.  
Methods: A cost-of-illness study was undertaken among 100 households affected by RHD in Cape 
Town. Healthcare costs, including direct and indirect costs, were estimated from a patient 
(household) perspective. The prevalence of coping strategies was also assessed, including both 
cost prevention and cost management strategies. Economic costs were valued in 2017 South 
African rand (ZAR). 
Result: One hundred index patients with RHD were included; supplementary socioeconomic data 
on household members (n = 479) were also collected. Healthcare costs totalled ZAR 123,000 (USD 
9400) (ZAR 1200 per patient per year (USD 90)), comprising ZAR 56,000 (USD 4200) in direct 
costs (all of which were direct non-medical costs) and ZAR 67,000 (USD 5000) in indirect costs. 
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Total inpatient (52% of direct costs and 39% of indirect costs) and outpatient (48% of direct costs 
and 61% of indirect costs) costs were estimated at ZAR 55,000 (USD 4200) and ZAR 68,000 
(USD 5200) respectively. At 10% and 40% threshold, four and eight percent of households 
incurred catastrophic health expenditure. Coping behaviours were frequent and included taking 
out loans (17% of households), receiving gifts from others (15%), and selling assets (2%). The 
estimated economic value of these behaviours was estimated at ZAR 40,000 (USD 3000). The 
total cost of RHD to the average affected household is valued at about ZAR 1600 (USD 100) 
annually. The estimated economic value of these behaviours was ZAR 40,000 (USD 3000). 
Conclusions: The economic impact of RHD in South Africa is substantial despite government 
efforts to provide free care. The total cost of RHD to the average affected household is valued at 
about ZAR 1600 (USD 100) annually. A broader and more robust range of social policies will be 
required to mitigate non-medical and indirect costs and reduce distortions in household economic 
activity.  
Keywords: Economic burden; cost of illness; direct cost; coping mechanism, Non-communicable 
disease 
3.1.BACKGROUND 
Chronic, non-communicable diseases in South Africa have become a public health issue requiring 
urgent attention. One neglected non-communicable disease is rheumatic heart disease (RHD), a 
major cause of cardiovascular disease among children and working-age adults in low- and middle-
income countries (Watkins et al., 2016b). RHD is a condition of poverty that results from recurrent 
episodes of acute rheumatic fever (ARF), a delayed complication of sore throat due to group A 
streptococcal infection, which mostly affects children aged 5-14 years (Sliwa et al., 2010, Cilliers, 
2014, Otto, 2004). It is estimated that in 2015 there were 320,000 deaths from RHD and 33 million 
people living with the condition globally (Watkins et al., 2017b). RHD can complicate pregnancy, 
82 
 
and high maternal and foetal death rates have been noted in some South African studies (Sliwa et 
al., 2014, Soma-Pillay et al., 2008). A recent systematic review of the incidence, prevalence, and 
outcomes of RHD in South Africa over the past 20 years estimated a prevalence of 20.2 cases of 
RHD per 1,000 school-aged children (Zühlke et al., 2014, Zühlke et al., 2015a). 
The economic burden of diseases refers to the economic (opportunity) costs that ill health poses 
for individuals, households, healthcare systems, and societies at large (National Collaborating 
Centre for Infectious Diseases, 2016). Economic burden of disease studies seeks to measure the 
direct and indirect costs incurred due to illnesses or injuries. To estimate the economic burden of 
disease, four approaches can be taken. The cost of illness (COI) method estimates the direct and 
indirect cost of illness for a certain population in a given time frame (Ugaz, 2009). COI studies 
include the sum of all personal medical costs of care, including direct and indirect (opportunity) 
costs, the latter of which usually focus on productivity losses (Ugaz, 2009, Abegunde et al., 2007). 
Economic growth models assess the impact of ill health on a country’s gross domestic product 
(GDP) as mediated by changes in labour supply, saving rate, capital accumulation, productivity, 
and income and investment (Ugaz, 2009). The value of a statistical life (VSL) approach measures 
willingness to pay to avoid an increased risk of death and then calculates the welfare losses 
associated with increased mortality (Bloom et al., 2017). A variant on the VSL approach, the full 
income approach, looks at the societal value of welfare losses from ill health (or welfare gains 
from improved health) valued in monetary terms, including changes in national income (GDP) 
(Andrade, 2009). 
The COI approach was developed by Rice et al. as a method for estimating the microeconomic 
impact of any kind of disease (Ugaz, 2009). COI studies have been popular in the medical 
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literature, particularly for chronic diseases like cardiovascular disease  (Ogah et al., 2014). These 
studies have also been conducted for cancers (Wang et al., 2016) and for HIV (WHO, 2015, De 
Vries et al., 2007). Beyond quantifying costs, some studies look at the impacts of ill health on 
household spending, purchase and sale of assets, and intra-household labour supply (Yamano and 
Jayne, 2004, Mujinja and Over, 1993, Menon et al., 1998). This extended use of COI can highlight 
the economic consequences of chronic diseases in nuanced ways and provide insight into the 
knock-on effects of diseases on household economic activity. A recent review found very little 
published evidence on the economic impact of RHD in low- and middle-income countries, 
including countries in Africa where RHD is highly endemic (Watkins et al., 2017a, Prabhakaran 
et al., 2017). Understanding the economic impact of RHD is very relevant to global and national 
research and policy agendas, especially as the non-communicable disease agenda broadens to 
include more “neglected” conditions like RHD (Bukhman et al., 2015). Because RHD affects 
income-vulnerable populations and – disproportionately to other noncommunicable diseases – 
children and working-age adults, it is likely that the economic impact of the condition is very high 
relative to its impact on population health. The present study is a COI study that looks at the impact 
of RHD in the Western Cape Province, taking a patient and household perspective on costs. 
3.2. METHODS AND MEASUREMENTS 
Theoretical considerations 
A conceptual model of the household economic impact of illness was proposed by McIntyre and 






Figure 1. Conceptual model of the household economic impact of ill health. Adapted from: 
(McIntyre et al., 2006) 
This study focusses on measuring direct costs, indirect costs, and economic behaviors (coping 
strategies) that lead to medical impoverishment which leads to poverty trap. 
Direct costs 
Direct costs comprise both medical and non-medical costs, which may include both the financial 
cost of resources as well as opportunity costs (e.g., of capital items). The total direct cost of illness 
is the sum of all direct medical costs and all direct non-medical costs. The direct medical costs 
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include cost of consultations, tariffs (for inpatients), drugs/medicines, vitamins/supplements, and 
laboratory tests and radiology studies. The direct non-medical direct costs of seeking healthcare 
included the cost of special food, transport to get to health facilities, and household purchases for 
healthcare. In this study, I asked about direct medical costs expecting “no” as a response, since 
public healthcare is generally free for poor people in South Africa. (Kruk et al., 2008).  
Indirect Costs  
The most commonly used method to calculate indirect cost in COI studies is human capital 
approach (Wang et al., 2016). Implicit in the human capital approach is the assumption that 
changes in health status of household members can be reflected by losses in productivity and losses 
in income generation. The value of lost income can be estimated using the prevailing average wage 
rate and applying it to the time lost by the patient or caregiver when engaged in RHD-related 
activities: 
Indirect cost (inpatient care) = Number of inpatient days ÷ number of days worked per month × 
monthly average wage  
Indirect cost (outpatient care) = Number of outpatient hours missed from work ÷ number of hours 
worked per month × monthly average wage 
Given that the majority of individuals with RHD are unemployed (see below), average productivity 
losses can be estimated using a proxy for opportunity cost among the poor, the minimum wage. 
South Africa’s new official minimum wage is ZAR 3500 per month, which can be converted to 
hourly lost productive time by assuming 20 days’ work per month and 8 hours’ work per day 




I also assessed the coping mechanisms employed in response to the economic burden of RHD 
(Figure 1). These included both patient and household behaviors. Coping strategies can be a clear 
response to direct costs (e.g., borrowing from friends or relatives, or taking out formal loans) or 
indirect costs (e.g., intra-household labor substitution) and can be cost prevention strategies (e.g., 
ignoring illness, non-treatment) to cost management strategies (e.g., borrowing, selling assets, or 
labor substitution).  
Methods and data sources 
This study was a follow-on study from the Global Rheumatic Heart Disease Registry (REMEDY), 
which was a multi-center, international, hospital-based prospective registry of patients with RHD. 
It was designed as a cohort study to document the disease characteristics and outcomes of 
individuals with RHD across many countries (Karthikeyan et al., 2012, Zühlke et al., 2015a). 
REMEDY participants were enrolled across 25 sites in 12 African countries as well as in Yemen 
and India; enrolment was based on a primary diagnosis of symptomatic RHD based on clinical and 
echocardiographic criteria (Zühlke et al., 2015a, Fever, 2004). I recruited participants in the 
REMEDY study who were resident in Cape Town and received care at Groote Schuur Hospital 
(GSH). This study made use of patient and household member surveys to estimate the economic 
consequences of RHD among households in which REMEDY participants reside. The conceptual 
framework (Figure 1) was used as a guide during the analysis. This framework allowed me to track 




Study population and sampling approach 
This study was carried out between January 2017 and February 2018. The units of analysis were 
households affected RHD, including REMEDY registry participants (index cases), their 
caregivers, and other household members. The target sample size focused on recruiting 100 
REMEDY participants receiving care at GSH since some patient have already grown from children 
to adult. So, children that were just recruited were not sampled. This sample size was chosen to 
balance feasibility and precision and to align with a parallel study of the cost of RHD to the health 
system that aimed to sample medical records from the same 100 REMEDY participants. I expected 
that our sample size of 100 would allow for an approximately 5% margin of error on key estimates 
such as cost of care. I screened participants for recruitment by randomly sampling names and 
associated contact details from the REMEDY database.  
Recruitment Strategy  
 I worked closely with the REMEDY data management officer to recruit participants in this sub-
study. Patients who answered the recruitment call and agreed to participate were visited at their 
residence with their primary caregiver or any household member older than eighteen years who is 
also a caregiver. Names and contact details for individuals who were not reachable or/and chose 
not to participate were destroyed, and new participants were recruited until 100 participants in total 
had consented to participate. Names and contact details of consenting participants were kept 
confidential at the REMEDY office.  
Data collection instruments and procedures  
The recruitment process identified the index patient, to whom I administered a structured 
questionnaire that included demographic, health, and economic data (appendix A). The individual 
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questionnaire included RHD-specific cost of illness variables, e.g., direct medical cost and direct 
non-medical cost, indirect costs, and coping mechanisms (see below). The cost section looked at 
both outpatient and inpatient costs over the past 12 months. All cost estimates were obtained via 
patient or household member self-report and were asked during data collection in 2017, implying 
a default currency/year of July 2017 South African rand (ZAR) converted to (USD) for the cost 
estimates in this study. Thereafter, one household member was invited to serve as a representative 
to answer a structured questionnaire on household demographic, health, and economic data 
(appendix). The household questionnaire also elicited the respondent’s assessment of the ways in 
which the household had coped with the cost of RHD, e.g., intra-household labor substitution or 
sale of assets (see below). Preference were given to head of household or their spouse, but I 
accepted participation of any reliable household member that was able to reflect on the total 
welfare of the household (i.e., reliably discuss household finances and decision-making). Research 
assistants who were data collection experts were hired to administer the questionnaires in the 
language that participants preferred (usually Afrikaans or isiXhosa).  
3.3.DATA ANALYSIS 
Data were entered in Epi-Info then exported to Microsoft Excel 2016 and STATA 13 (StataCorp 
2013) for analysis. I estimated the average yearly cost of RHD to the index patient and household, 
including the share due to direct and indirect costs and to inpatient and outpatient care. I then 
estimated the prevalence of coping strategies (intra-household labor substitution, borrowing, 
selling assets, etc) for RHD. Drivers of total cost were assessed using ordinary least squares 
models, and predictors of coping mechanisms were assessed using logistic regression models. The 
independent variables assessed in these models were: age, patient EQ-5D score, household number 
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of persons with multi-morbidity, gender, number of inpatient admissions, educational attainment, 
employment status, household assets, and marital status. 





Table 1 presents the demographic characteristics of the participants in this study. There were 200 
adult respondents in total: 100 index patients with RHD and 100 household members representing 
479 individuals without RHD residing in these 100 households. Sixty-seven percent of index 
patients were female compared with 58% of household members. The mean patient and household 
member ages were 48 and 43 years respectively. Over four-fifths of patients and household 
members were currently unemployed, though roughly the same proportions had achieved 
secondary education.   
Many household members were affected by multimorbidity, defined as the presence of two or 
more chronic health conditions. Table 1 shows about a quarter of household members had 
multimorbidity as compared with 5% of index patients with RHD. Nearly all patients and 
household members were uninsured. The average household and individual patient monthly 
income was estimated (by self-report) at ZAR 3000 (USD 200) and ZAR 2000 (USD 150), 
respectively. Total household expenditure (food and non-food) was estimated at ZAR 2700 (USD 
200), with ZAR 1000 (USD 70) being non-food expenditure. The questionnaire also asked about 
household assets. We used principal component analysis to create a household wealth indicator 
variable based on the first principal component (data not shown; see regression analyses below). 
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Table 1. Baseline characteristics of sampled patients and households 
 
Characteristic Patients       
Household Members with 
100 RHD patients      
N=479 
Mean household size                               5.79 (min = 2; max = 9) 
Female Gender, n (%) 67(67) 277(58) 
Educational Level (%) 
Grade 1-3 3(3) 23(5) 
Grade 4-6 11(11) 28(6) 
Grade 7-12 81(81) 402(84) 
Undergraduate 4(4) 14(3) 
Marital status (%) 
Single 36(36) 201(42) 
Married 56(56) 234(49) 
Divorced/ Widow/widower 8(8) 38(8) 
Lack of Employment (%) 84(84) 387(81) 
Multimorbidity  
Prevalence of Multimorbidity (%)  5 23  
Lack of Medical Aid, n (%) 99(99) 469(98) 
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Age Distribution  
Patient   Household Member  
20-35 16(16) 20-35 148(31) 
36-45 45(45) 36-45 143(30) 
46-55 29(29) 46-55 86(18) 
55+ 10(10) 56-71+ 100(21) 
Patient Age, Mean±S.D 48±13 
Household Member Age, 
Mean±S.D 
43±13 
Household Income and Expenditure (ZAR)                                                           
Average monthly household income  3000 (USD 220) 
Total expenditure 2700 (USD 200) 
Average monthly household expenditure, 
food                                                
1700 (USD 130) 
Average monthly household expenditure, 
non-food                                           
1000 (USD 70) 
 
 
Direct medical and direct non-medical costs 
 
Table 2 demonstrates the estimated total costs (sum of direct and indirect costs) represented as the 
total costs (in the sample of 100 index patients) and average cost per index patient. Direct medical 
cost was estimated to ZAR 0, because all patients were exempt from medical fees. Total direct 
non-medical cost for outpatient and inpatient visits was estimated to be ZAR 27,000 (USD 2000) 
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and 29,000 (USD 2200) (respectively) over 302 and 74 encounters (respectively), an average of 
ZAR 270 (USD 20) and ZAR 290 (USD 20)  per patient (respectively).  
Indirect costs 
Indirect costs incurred over the 302 outpatient encounters and 74 hospital admissions were 
estimated to be ZAR 41,000 (USD 3000) and ZAR 26,000 (USD 2000) (respectively), an average 
of ZAR 410 (USD 30) and ZAR 260 (USD 20) per patient (respectively).  
 
Table 2. Estimated cost of RHD to patients 
Cost 
component 
Aggregate costs among 100 
participants 






































































The prevalence of catastrophic health expenditure in this sample was calculated using two 
approaches (Table 3). The prevalence of RHD-related expenditure exceeding 10% of total 
household expenditure was estimated at 8%. The prevalence of RHD-related expenditure 




Direct costs posed a significant burden to households, stimulating a range of coping responses 
among a minority of households (Table 3). Seventeen percent of households took out loans at mean 
of ZAR 1200 (USD 90) per loan (range ZAR 100 to ZAR 7000) (USD  7 to 500).  Fifteen percent 
received financial gifts at an average of ZAR 800 (USD 60) per gift. Two percent sold assets 
valued at ZAR 5600 (USD 400) on average. Five percent engaged in multiple coping strategies. 
To cope with the indirect costs of illness, 15% of household caregivers changed jobs and 10% 
worked extra hours. About 4% of household members dropped out of school. Four percent adopted 
more than one coping strategy. A considerable share of participants reported that they had reduced 
education to take care of the affected patient. Most of the caregivers of patients with RHD were 
spouses and children, and 6 % were heads of household. 
The total economic value of all these coping strategies across the entire sample was estimated to 
be ZAR 40,000 (USD 3000), with an average per-patient economic value of coping of ZAR 1100 
(USD 80).  
Table 3. Coping strategies among patients with RHD  
































































15 1.9 0.33 1 2 
Work extra hour  10 1.9 0.36 1 2 
School drop out  4 1.9 0.30 1  2 
Multiple 4 3 0 1 4 
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Intrahousehold Burden (Caregiver) 
Head of the household 6 
Primary caregiver (%) 
Spouse                                                                                                                         39 
Own child                                                                                                                   31 
Mother/father                                                                                                               9 
(Others)                                                                                                                       15 
What caregiver gave up in taking care 
of RHD patient…. 
Frequency (n = 100) 
forgo employment                                                                                                          15 
Reduced education                                                                                                        44 
Work extra hour                                                                                                            10                         
Reduce hour work                                                                                                         11 
Multiple                                                                                                                         3 
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Total number of patients with 







Total economic value of coping in the 
sample ZAR 40,000 
Average economic value of coping mechanisms per 
patient                        ZAR 1100 (USD 80) 
Proportion of HH coded 1 for 




Predictors of high cost and coping strategies 
 
We performed two sets of regression analyses to explore potential predictors of high total cost 
(Table 4) and of the use of any coping strategies (Table 5). The number of persons with 
multimorbidity in a household, number of household asset and the number of inpatient admissions 
were found to be significantly associated with total cost; the number of inpatient admissions was 
found to be significantly associated with the use of one or more coping strategies. It should be 
noted that the study was not designed specifically to estimate any of these associations, and the 
small sample size and low event rate makes it quite possible that the analysis was underpowered 




Table 4. Predictors of high cost 
 
Independent variable Point estimate of 
coefficient 














Patient EQ-5D score -2.01 [-4.12, 0.09] 
Household number of persons with 
multimorbidity 




















Household asset measure (see text for 
details) 
0.14 [0.05, 0 .23]** 
Lack of employment -0.13 [-0.49, 0.23] 





-0.5        
0.5 
[0.01,   0.07] 
  [-0.2, 0.3] 
 
 
Table 5. Predictors of the use of a coping strategy  
 
 
LIST OF COVARIATES POINT 
ESTIMATE OF 
BETA 
95% CON FIDENCE 

























EQ-5D score -0.15 [-0.63, 0 .33] 
Household number of persons with 
multimorbidity 
1.07 [-0.34, 2.47] 
Number of inpatient admission 0.02 [0.02, 0.32]** 












Household asset measure (see text for 
details) 
-0.22 [-0.60, 0.15] 
Female gender 0.09 [-0.74, 0.92] 
** is used to know if any independent variable is statistically significant at 95% CI ** 
 
3.5. DISCUSSION 
The findings confirm that RHD mostly affects productive individuals of working age, although 
because of their illness and conditions of poverty, unemployment is very high. This is the major 
finding of your work-In monetary terms, a little more than half of the total cost of RHD care was 
indirect, consistent with studies of other chronic diseases (Russell, 2004, Segel, 2006a, Wang et 
al., 2016, Ogah et al., 2014, Tharkar et al., 2010) Although the government of South Africa 
provides extremely low-cost health care services to low-income households, covering the cost of 
nearly all persons affected by RHD, the direct non-medical and indirect costs in this study were 
high. This finding is consistent with studies conducted in Zambia and Malawi on other health 
conditions: though essential health services are provided free of charge, households still incur 
significant costs (Russell, 2004, Lara R., 2009), Wang et al., 2016). 
Direct (non-medical) costs and indirect costs of RHD were estimated to be ZAR 560 (USD 42) 
and ZAR 670 (USD 51) (respectively) per patient yearly. Among those pushed into financial 
hardship, the economic cost of coping strategies contributed an additional ZAR 1100 (USD 80). 
In total, the overall annual economic impact of RHD in this sample of 100 households affected by 
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RHD was estimated at ZAR 160,000 (USD 12000)  (ZAR 1600 (USD 120)  per household), 
representing 4.4% of annual household income or 4.9% of annual household expenditure. This is 
similar to a study of HIV/AIDS and tuberculosis in which annual direct costs were estimated to be 
between 2.5% and 7.0% of income (Russell, 2004).    
This study underscores that it is insufficient to look at direct and indirect costs alone; understanding 
the impact of coping strategies is crucial to getting a full picture of the economic impact of illness 
(Sauerborn et al., 1996, Russell, 2004, McIntyre and Thiede, 2003).  About 17% of households 
affected by RHD took out loans or engaged in other coping activities, with 5% employing more 
than one strategy (Sauerborn et al., 1996). Again, these findings are broadly consistent with studies 
of HIV/AIDS and tuberculosis that show how households struggle with direct and indirect costs 
and deplete assets, leading to or reinforcing poverty traps (Russell, 2004, Sauerborn et al., 1996). 
This study also shows that it is not just patients who are affected: significant numbers of caregivers 
in this study had to give up educational or employment opportunities in order to provide care. 
Other caregivers would work extra hours to compensate for losses elsewhere in the household or 
the cost of healthcare itself. Since RHD is a chronic condition, these effects on caregivers are 
probably long-lasting in most cases.(Segel, 2006a) 
Finally, we found that the number of inpatient admissions was significantly associated with both 
total cost and coping strategies. This result is not surprising, since direct and indirect costs are 
probably correlated with length of stay, and high costs (e.g., of surgical care) are more likely to 
trigger coping strategies. The finding that higher levels of household multimorbidity were 





• This prevalence-based estimate looks at the current cost across a one-year period. If costs 
extend more than a year period, which they likely do, then incidence-based estimates will 
provide more robust information about costs 
• This study was limited by sample size (100 participants and households), which may have 
led to false negative results in the regression analyses. This study only focussed on the 
urban area of Cape Town, so its generalisability is limited. A cross-province comparison 
study, capturing both rural and urban areas of South Africa, would likely lead to more 
representative estimates   
• Recall bias due to overestimation or underestimation of indirect costs might have occurred 
because of over-reporting or under-reporting of time loss, particularly for events that 
occurred more than 30 days ago 
• As it is recognized in economic evaluation literature, minimum wage might not be a true 
reflection of informal section in South Africa. 
Policy recommendations 
These findings point at clear gaps in financial protection and call for further investments not just 
free healthcare and disability grants, but a range of social protection programs, such as 
transportation subsidies, remuneration for caregivers, and remediation of lost opportunities for 
employment and education. These costs are likely to be substantial, and evidence is needed on 
which government programs are most effective and efficient at providing social protection at 
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The household economic impact of Rheumatic Heart Disease (RHD) in South Africa 
Author: Oyebamiji Oyeleke, University of Cape Town, February 2018. 
INTRODUCTION  
Rheumatic heart disease (RHD) is a frequent cause of cardiovascular disease among children and 
working-age adults in LMICs. RHD results from repeated episodes of acute rheumatic fever 
(ARF), a delayed complication of sore throat due to group A streptococcal infection, which mostly 
afflicts children aged 5-14 years. The risk factors for RHD include poverty, overcrowding, 
malnutrition, poor sanitation, and low educational attainment, as well as poor access to primary 
care for treatment of sore throat. A recent systematic review of the epidemiology of RHD in South 
Africa found favorable trends in mortality since the 1990s, probably owing to better access to 
surgical care for severe disease, but persistently high rates of disease incidence and prevalence, 
suggesting insufficient progress on addressing the social determinants of RHD.  
The study of the household economic impact of RHD is very relevant to the South African 
noncommunicable disease research and policy agenda. This chronic health condition 
disproportionately affects learners and wage-earners, so its economic impact– including its effects 
on educational attainment and productivity – is likely to be very high. To date, there has been no 
research on the household economic impact of RHD in South Africa (or other African countries, 
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for that matter), so the findings presented below represent a novel contribution to the literature and 
can inform policy and advocacy efforts. 
RESEARCH OBJECTIVE 
The objective of this study was to estimate the direct and indirect cost of RHD from the patient 
perspective and explore the impact of RHD on the economic well-being of affected households, 
including coping mechanisms to address the cost of RHD. 
METHOD 
A cross sectional cost-of-illness study from the patient perspective was conducted among 100 
households affected by RHD. Index cases with RHD were identified from the REMEDY study 
site at Groote Schuur Hospital (GSH) in Cape Town. (REMEDY is a two-year, multi-country 
cohort study of patients affected by RHD.) Heads of household or other household members 
designated as decision-makers (i.e., able to respond to economic questions on behalf of all 
household members) were also included. 
Two data collection instruments were designed and administered, one to the 100 index cases, and 
another to 100 household representatives responding on behalf of 479 household members. The 
average yearly cost of RHD to the household was estimated, including the breakdown between 
direct and indirect costs. The prevalence of coping strategies – such as intra-household labor 
substitution, borrowing, and selling assets – was also estimated. Predictors of cost and of coping 
were also assessed using regression analyses. Children were not included in this study because the 
REMEDY patient folders used are adult folder who could respond to contact calls and available to 
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be visited at their residence. Furthermore, this is the first stage of this study, further study would 
investigate on children and can compare both children and adult results for policy making.   
FINDINGS 
Estimates of direct and indirect cost 
• Annual direct costs were ZAR 560 per patient. These were all non-medical costs such as 
food and transportation. Annual indirect costs were ZAR 670 per patient. Total annual costs were 
ZAR 1200 per patient. A higher number of inpatient admissions and higher levels of household 
chronic health conditions were predictors of higher total costs. 
Coping strategies 
• The prevalence of catastrophic health expenditure was between 4% and 8% depending on 
the method used. About 34% of households engaged in some type of coping mechanism, including 
taking out loans (17%), receiving gifts (15%), or selling assets (2%). Five percent of households 
engaged in more than one coping mechanism. The average economic value of coping strategies 
among those engaging in them was ZAR1100. A higher number of inpatient admissions was a 
predictor of engaging in coping strategies.  
Other findings 
• About 15% of household caregivers changed their jobs and 10% worked extra hours to 
provide care for individuals with RHD. Four percent dropped out of school, and another 4% gave 
up employment  
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• Most of the caregivers are spouses and children of the patient in the household and about 
6 % of household head became caregiver to take care of the RHD patients. Aggregate of all HH 
coping strategies and average per patient in the sample was estimated by adding all the coping 
strategies adopted each by the caregivers to be ZAR 40000 ZAR 7000 respectively. 
POLICY IMPLICATIONS 
• This study underscores the importance of RHD prevention to reduce both health and 
economic consequences to poor households 
• It also reinforces previous literature (i.e., on other diseases) on the importance of direct 
non-medical costs in the South African context  (Meyer-Rath and Ritchie, 2007) 
• These findings point at clear gaps in financial protection and call for further investments –
not just free healthcare and disability grants, but a range of social protection programs, such as 
transportation subsidies, remuneration for caregivers, and remediation of lost opportunities for 
employment and education. These costs are likely to be substantial, and evidence is needed on 
which government programs are most effective and efficient at providing social protection at 








APPENDIX A: RESEARCH QUESTIONNAIRE 
HOUSEHOLD BURDEN OF RHD PILOT QUESTIONNAIRE (2017) 
SECTION A: PATIENT INFORMATION 
A01. State/ province name: 
_______________________________
__ 
Code                                                                
 
A02.  AREA name: 
__________________________________ 
Code                                                               
 
 A03. EA Name: 
_______________________________
____ 
Code                                                 
 
A 04. EA sector:  
Urban = 1, Rural = 2                                                            
 
 A05. Household number:             
                                                                                         
 
 A06. Name of head of household:  
__________________________________________
______ 
 A07. Interviewer’s name: 
___________________________ 
Code                                                                  
 
 A08. Supervisor’s name: 
____________________________ 
Code                                                                  
 
A09. Date of interview (DD/MM/YY):                                                                                            
  /    /   
 




a) Date (DD/MM/YY) b) Time started  
(24 hours’ time) 





(Male=1        
Female= 2) 
I 





















Completed = 1, Partially completed = 2, Refused = 3, No suitable respondent at home = 4, No 





a) Do you have any questions 
right now? 
Yes = 1, No = 2 
b) Are you willing to proceed with 
this interview?   
Yes = 1, No = 2 
01   
 








































































Yes = 1 
No=2  
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ower = 4 
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[ 02 ] 
  
 
      
 
[ 03 ] 
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SECTION C: OTHER CHRONIC HEALTH CONDITION 
A list has been provided below for HH members answering question D01 (D01a-e). Household 
members can list more than one category if applicable 
For the line below. We want to know about the health condition of specific household 
members. So, line A is person 1, line B is person 2………. Line E, person 5 






Does anyone in this house currently suffer from 
any one/more of this condition? 
HIV 








                         Yes 
=1 
 
                          No=2 
                                                       
                       
 
 










































SECTION D: HOUSEHOLD INCOME  
 QUESTION CODING 
CATEGORIES 
ANSWER 





E02 How much grant do you receive per month from? 
 
 
A Disability grant  _______________ 
R/month 




C Child support grant   _______________ 
R/month 
D Foster care grant   _______________ 
R/month 
E Care dependency grant   _______________ 
R/month 
F War veteran pension   _______________ 
R/month 
G Inheritance  _______________ 
R/month 
I Sale of household good   _______________ 
R/month 











SECTION E: HOUSEHOLD INCOME CONTINUATION 
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For the list E06 (A-D) below. We want to know other income earners in this household. So, 
line A is person 1, line B is person 2………. Line D, person 5 
 QUESTION CODING CATEGORIES ANSWER 
E04 Who is the primary income earner 
in the household? 
Patient = 1 
Wife/mother = 2 
Husband/father = 3 
Extended family = 4  





E05 How much income does the 




E06 Does anyone else earn income? 





A  Patient = 1 
Wife/mother = 2 
Husband/father = 3 
Extended family = 4  
Son/daughter = 5 
Other (specify):………….. 
 
B  Patient = 1 
Wife/mother = 2 
Husband/father = 3 
Extended family = 4  
Son/daughter = 5 
Other (specify):………….. 
 
C  Patient = 1 
Wife/mother = 2 
Husband/father = 3 
Extended family = 4  
Son/daughter = 5 
Other (specify):………….. 
 
D  Patient = 1 
Wife/mother = 2 
Husband/father = 3 
Extended family = 4  





E07 Was your household income 
substantially higher before patient 
was diagnosed with RHD? 
 





E08 How much more per month?   
_____________R 
 
SECTION F: HOUSEHOLD ASSETS 
 QUESTION CODING 
CATEGORIES 
ANSWER 

















F03 What kind of toilet facility do 
members of your household use? 
Flush to piped sewer 
system = 10 
Flush to septic tank = 11 
Flush to pit latrine = 12 
Flush to somewhere else = 
13 
Flush, don’t know where 
= 14 
Ventilated improved pit 
latrine = 15 
Pit latrine with slab = 16 
Pit latrine without 
slab/open pit = 17 
Composting toilet = 18 
Bucket toilet = 19 
Hanging toilet/hanging 
latrine = 20 
No facility, bush, field = 
21 
Other = 88 
 
 
F04 Do you share this toilet facility 
with other households? 
Yes = 1 
No = 2 
 
















Yes = 1 









Cable TV  
Generating set  
Air conditioner  
Computer  
Electric iron  
Fan  
F09 What material is used to construct 
the floor of your house? 
Earth/sand = 10 
Dung = 11 
Wood planks = 12 
Parquet or polished wood 
= 13 
Vinyl or asphalt strips = 
14 
Ceramic tiles = 15 
Cement = 16 
Carpet = 17 
Other = 98 
Don’t know = 97 
Refuses to respond = 99 
 
 
F10 What material is used to construct 
the roof of your house? 
No roof = 10 
Thatch/palm leaf = 11 
Sod = 12 
Rustic mat = 13 
Palm/bamboo = 14 
Wood planks = 15 
Cardboard = 16 
Corrugated iron sheets = 
17 
Metal = 18 
Wood = 19 
Calamine/cement fiber = 
20 
Other = 98 





Refuses to respond = 99 
F11 What material is used to construct 
the exterior walls of your house? 
No walls = 10 
Cane/palm/trunks = 11 
Dirt = 12 
Rudimentary walls = 13 
Bamboo with mud = 14 
Stone with mud = 15 
Uncovered adobe = 16 
Plywood = 17 
Cardboard = 18 
Reused walls = 19 
Cement = 20 
Stone with limit/cement = 
21 
Bricks = 22 
Cement blocks = 23 
Uncovered adobe = 24 
Wood planks/shingles = 
25 
Other = 98 
Don’t know = 97 
Refuses to respond = 99 
 
 
F12 How many rooms are used for 
sleeping in your household? 
  
Number of rooms 
 
F13 How many people sleep together in 




Four persons =4 
Five persons=5  









A motorcycle or motor scooter? 
An animal-drawn cart? 
A car or truck? 
A boat with a motor? 
A canoe? 
 
Yes = 1  













F15 Does any member of this 
household own any agricultural 
land? 
Yes = 1  
No = 2 → 17 
 
 
F16 How many plot/acres/hectares of 
agricultural land do members of 
this household own? 
 
IF 95 OR MORE, CIRCLE ‘9950’ 
  
95 or more 
plots/acres/hectares = 
9950 
Don’t know = 9998 
 
Enter amount:  
Plot  .  
Acres  .  
Hectares  .  
 
F17 Does this household own any 
livestock, herds, other farm 
animals, or poultry? 
Yes = 1  
No = 2 → 18 
 
 
F18 How many of the following 
animals does this household own? 
 
IF NONE, ENTER ‘00’ 
IF MORE THAN 95, ENTER ‘95’ 
IF UNKNOWN, ENTER ‘98’ 
 
Milk cows or bulls? 




























SECTION GA: HOUSEHOLD EXPENDITURE (FOOD) 
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 QUESTION CODING 
CATEGORIES 
ANSWER 
FOOD EXPENDITURE: Now we would like to ask questions about some specific food that 
may have been eaten in the LAST30 DAYS. It should not include food that has been bought 
for resale or exchanged for commercial purposes. 
GA01 Within the last 30 days, what 







GA02 Within the last 30 days, did you 




Yes = 1 
No = 2 
Refuse=3 
Don’t know = 99 




GA03 Within the last 30 days, did you 
by any chance produce /grow/ 
gather any foodstuffs? 
 
Yes = 1 
No = 2 
Refuse=3 
Don’t know = 99 
 
GA04  Within the last 30 days, did you 
eat food from your own stock 
shop or bought at the mall? 
Yes = 1 ( own stock 
shop) 
No = 2 (stock shop) 








SECTION GB: HOUSEHOLD EXPENDITURE (NON-FOOD) 
In this part of the questionnaire, we would like to ask questions about some specific household 
items on which the household may have spent money in the LAST 30 DAYS and how much was 
spent on these items. It should not include items that has been bought for resale or exchanged for 
commercial purposes. 





QUESTION CB01 CG02 
GB01 Within the last 30 days, what was the 









Within the last 30 
days, did anybody in 
the household spend 
money on [...]?  
                                                                          
 
Yes = 1 (mall) 
No = 2 (mall) 




If No, skip to next. 
Yes          No 
In the last 30 days, 
how much was spent 
on [...]?  
Amount in Rands  
 
a Car payments excluding insurance  
 
1             2                                                                              
b Petrol, oil and car service  
 
1             2                                                                              
c Buses, taxis, trains and air tickets 
including transport to school, work 
etc. 
1             2  
 Energy, water and municipal rates  
 
  
d Water  
 
1             2  
e Electricity  1             2  
f Other energy sources such as wood, 
paraffin, charcoal/coal, candles, gas, 
purchasing/charging batteries and 
diesel oil for generators  
 
1             2  
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g Levies, for example sectional title, 
share block and timeshare  
 
1             2  
h Municipal rates  
 
1             2  
 Household items: 
 
  
i Kitchen equipment, like pots and 
pans, cutlery and crockery  
 
1             2  
j Home maintenance and repairs to the 
dwelling  
 
1             2  
k Bedding, sheets, blankets and towels  
 
1             2  
 Miscellaneous:  
 
1             2  
l Washing powder, dishwashing liquid, 
polish and all household cleaners  
 
1             2  
m Religious and membership dues of 
organisations, donations to charity  
 
1             2  
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n Pets  
 
1             2  




HOUSEHOLD EXPENDITURE CONTINUATION 
 
GBO2 What was the total food expenditure 





GB03 Would you say the total food expenditure for this household in the last 30 days was 
a More than or less than R1200? More than =01 
About equal =02 




b More than or less than R750? More than =01 
About equal =02 




c More than or less than R500? More than =01 
About equal =02 






d More than or less than R750? More than =01 
About equal =02 




e More than or less than R 1800? More than =01 
About equal =02 




f More than or less than R 3000? More than =01 
About equal =02 




g More than or less than R5000? More than =01 
About equal =02 















SECTION H: INTRAHOLUSEHOLD BURDEN (CAREGIVING)  
 QUESTION CODING 
CATEGORIES 
ANSWER 
H01   Who is the primary 
caregiver of the person with 
RHD in this household? 
 
 See code 1                 
H02  
 What did the caregiver give 
up to take care of the RHD 
patient? 
 









H03 Did the primary caregiver 
had to forgo his/her 
employment or work to 




Yes = 1 
No = 2 
Don’t know = 99 







SECTION I: HOUSEHOLD COPING STRATEGIES 
 QUESTION CODING 
CATEGORIES 
ANSWER 
I01 What kind of coping strategies has the household member put in place      Take a job 
H04 As the person significantly 
reduced the number of hour 





Yes = 1 
No = 2 
Don’t know = 99 
If No/ don’t know >>I01                    
 
  
H05  If answer to question H03 is 
YES, 
                                                        
How Much? 
If NO, (skip → Section I) 
 ____________R 
H06 Has anyone else in the house 
had to take an extra job or 
work or extra hour to 
compensate for the RHD 
patient? 
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                                                                                                                       Drop out of 
school                                                                                   
____________                                     
                                                                                                                      Other please 
specify 
In the last 12 month, has your household had to do any of this thing (………) due to the 
patient with RHD? 
 
I02  Spend savings? Yes = 1 
No = 2 
Don’t know = 99 
 
 
How much?  
_________________R 
 
I03 Borrowed from financial 
institutions or agencies 
(microfinance schemes, banks…)? 
Yes = 1 
No = 2 
Don’t know = 99 
 
How much?  
_________________R 
I04 Sold items (land, property, 
furniture, livestock, 
jewellery…)? 
Yes = 1 
No = 2 
Don’t know = 99 
 
How much?  
_________________R 
I05  Borrow from relatives or friends 
from outside the household? 
Yes = 1 
No = 2 
Don’t know = 99 
 




I06 Spend current income of any 
household members (salaries, 
pensions, paid benefits…)? 
Yes = 1 
No = 2 
Don’t know = 99 
 
How much?  
_________________R 
  What other impacts does RHD 











APPENDIX: A Individual Patient burden of RHD SURVEY 
INDIVIDUAL BURDEN OF RHD QUESTIONNAIRE (2017) 
SECTION A: PATIENT INFORMATION 
A01. State/ province name: 
_______________________________
__ 




Code                                                                
 
Code                                                               
 
 A03. EA Name: 
_______________________________
____ 
Code                                                 
 
A 04. EA sector:  
Urban = 1, Rural = 2                                                            
 
 A05. Household number:             
                                                                                         
 
 A06. Name of head of household:  
__________________________________________
______ 
 A07. Interviewer’s name: 
___________________________ 
Code                                                                  
 
 A08. Supervisor’s name: 
____________________________ 
Code                                                                  
 
A09. Date of interview (DD/MM/YY):                                                                                            
  /    /   
 






a) Date (DD/MM/YY) b) Time started  
(24 hours’ time) 





     
(Male/Female) 
i 
 /  / 
   
 
ii 
 /  / 
   
 
iii 
 /  / 




Completed = 1, Partially completed = 2, Refused = 3, No suitable respondent at home = 4, No 




a) Do you have any questions right 
now? 
Yes = 1, No = 2 
b) Are you willing to proceed 
with this interview?   
Yes = 1, No = 2 





ECTION B: DEMOGRAPHIC  
 
B01 Sex Male=1 
Female=2 
 
B02 What is your 
date of birth? 


















Has (NAME) ever attended 
formal school  
 
Yes = 1 
                                                 






What is the highest grade 
(NAME) Completed? 
No education = 10 
 
Foundation phase 
Grade R/0 = 11 
Grade 1-3= 12 
 
Intermediate phase  
Grade 4-6 = 13 
 
Senior phase  
Grade 7-12 = 14 
 
Tertiary phase 
Undergraduate = 15 
Postgraduate = 16 
Other = 88  
Don’t know = 97 






B06a Employment Are you currently employed? 
 
Yes = 1 
No=2  
 
If No, (skip →Section C) 
 
B06b Employment Which of this best describe 
your work? 





    
 
 
SECTION C: DISABILITY (EQ-5D) 
By placing a tick in one box in each group below, please indicate which statements best describe 
your own health state today. 
Mobility 
I have no problems in walking about  
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I have some problems in walking about  
I am confined to bed  
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
Usual Activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
Anxiety/Depression 
I am not anxious or depressed  
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I am moderately anxious or depressed  











To help people say how good or bad a health state is, we have 
drawn a scale (rather like a thermometer) on which the best 
state you can imagine is marked 100 and the worst state you 
can imagine is marked 0.  
We would like you to indicate on this scale how good or bad 
your own health is today, in your opinion. Please do this by 
drawing a line from the box below to whichever point on the 




































SECTION D: INDIVIDUAL PATIENT INCOME, EXPENDITURES AND MEDICAL 
AID 
 QUESTION CODING 
CATEGORIES 
ANSWER 
D01 How much in total wages 
do you receive per month? 
 
 _______________ R/month 
D02 How much grant do you receive per month from? 
 
 
A Disability grant  _______________ R/month 
B State (South Africa 
government) old age grant 
 _______________ R/month 
C Child support grant   _______________ R/month 
D Foster care grant   _______________ R/month 
E Care dependency grant   _______________ R/month 
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F War veteran pension   _______________ R/month 
G Inheritance  _______________ R/month 
I Sale of household good   _______________ R/month 




 _______________ R/month 
D03 How much non-grant do 
you receive per month 
from? 
 _______________ R/month 
D04 MEDICAL AID 
A Do you have medical aid 
cover? 
 
Yes = 1 
No = 2 
Don’t know = 99 
                                                       
                        
 
 
B Is your medical aid 
sufficient for the treatment 
of RHD?  
Yes = 1 
No = 2 
Don’t know = 99 
                                                          
                   
C Do you face any challenge 
related to your medical aid 
cover? 
                                                           
______________________________                 
 
SECTION E: INPATIENT COSTS 




E01 “To your 
knowledge, 
have you been 
hospitalized 
for RHD 
within the past 
12 months?” 
Yes = 1 
No = 2 
Don’t know = 
99 
                                                       
                        
 
 
If answer to question E01 is YES>> question 2. If NO, >> section F 
 
E02 Thinking back to your most resent hospitalization for RHD, 
 
A Approximatel










B Do you pay 







Yes = 1 
No = 2 
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 How much in 
total do you 










was spent on, 
Laboratory test 
(blood, scan, x-
tray etc ) 





(No of bed ) 
____________ R 
Drug supply ____________ R 
C How much 
was spent 
on,… 





Food cost ____________ R 
Da On average, 
how many 
hours/days of 
work did you 
miss during 
you visit to 
the hospital? 
 _________________ hours 
 
B Did anyone 
accompany 
Yes = 1  
151 | P a g e  
 





No = 2 
 
  







Yes = 1 
No = 2 
 
 
D On average 
how much did 
the 
accompanying 




 ___________ R 
E03 Thinking about the last hospitalization before that one, 
 
A Approximatel










B Do you pay 





Yes = 1 
No = 2 









 How much in 
total do you 







y how much 


















(No of bed) 
____________ R 
Drug supply ____________ R 
C How much 
was spent on. 
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Food cost ____________ R 
Da On average, 
how many 
hours/days of 
work did you 
miss during 
you visit to 
the hospital? 
 _________________ hours 
 
B Did anyone 
accompany 





Yes = 1 











Yes = 1 
No = 2 
 
 
D On average 
how much did 
the 
accompanying 




 ___________ R 
E04 Thinking back to the hospitalization before that, 
A Approximatel










B Do you pay 







Yes = 1 
No = 2 





 How much in 
total do you 














____________ R               
  Consultation  
(doctors visit) 
____________ R 
  Hospitalization 
(No of bed) 
____________ R 
  Drug supply ____________ R 
C How much 
was spent on. 
 Transport  
____________ R 





  Food cost ____________ R 
Da On average, 
how many 
hours/days of 
work did you 
miss during 
you visit to 
the hospital? 
 _________________ hours 
 
B Did anyone 
accompany 





Yes = 1 











Yes = 1 
No = 2 
 
 
D On average 
how much did 
the 
accompanying 




 ___________ R 
E05 Thinking back to the hospitalization before that, 
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A Approximatel










B Do you pay 







Yes = 1 
No = 2 





 How much in 
total do you 














____________ R               
  Consultation  
(doctors visit) 
____________ R 
  Hospitalization 
(No of bed) 
____________ R 
  Drug supply ____________ R 
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C how much 
was spent on, 





  Food cost ____________ R 
Da On average, 
how many 
hours/days of 
work did you 
miss during 
you visit to 
the hospital? 
 _________________ hours 
 
B Did anyone 
accompany 





Yes = 1 











Yes = 1 
No = 2 
 
 
D On average 
how much did 
the 
accompanying 




 ___________ R 




Thinking about the last hospitalization before that one,  
 
A Approximatel










B Do you pay 







Yes = 1 
No = 2 





 How much in 
total do you 










was spent on, 
Laboratory test 
(blood, scan, x-
tray etc ) 
____________ R               
  Consultation  
(doctors visit) 
____________ R 
  Hospitalization ____________ R 
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(No of bed) 
  Drug supply ____________ R 
C how much 
was spent on, 





  Food cost ____________ R 
Da On average, 
how many 
hours/days of 
work did you 
miss during 
you visit to 
the hospital? 
 _________________ hours 
 
B Did anyone 
accompany 





Yes = 1 











Yes = 1 
No = 2 
 
 
D On average 
how much did 
the 
accompanying 
 ___________ R 
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SECTION F: CLINIC VISITS 
 QUESTION CODING 
CATEGORIES 
ANSWER 
F01 have you been 
to clinic for 
RHD in the past 
12 months 
Yes = 1 
No = 2 
Don’t know = 
99 
                                                       
                        
 
 
If answer to question F01 is YES>> question 2. If NO, >> section G 
                                                                             
F02 Thinking back to your most recent clinic visit… 







B Do you pay out 
of pocket 




Yes = 1 
No = 2 
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 How much in 
total do you pay 















(No of bed) 
____________ R 
Drug supply ____________ R 
C How much was 
spent on. 
 Transport  
____________ R 
  Accommodation  ____________ R 
  Food cost ____________ R 
Da On average, 
how many 
hours/days of 
work did you 
miss during you 
 _________________ hours 
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visit to the 
hospital? 
B Did anyone 
accompany you 
to the clinic 
during your last 
visit? 
 
Yes = 1 








because of this 
hospital visit? 
Yes = 1 
No = 2 
 
 
D On average 
how much did 
the 
accompanying 




 ___________ R 







B Do you pay out 
of pocket 




Yes = 1 
No = 2 
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 How much in 
total do you pay 









tray etc ) 
____________ R               
  Consultation  
(doctors visit) 
____________ R 
  Hospitalization 
(No of bed) 
____________ R 
  Drug supply ____________ R 
C How much was 
spent on. 
 Transport  
____________ R 
  Accommodation  ____________ R 
  Food cost ____________ R 
Da On average, 
how many 
hours/days of 
work did you 
miss during you 
visit to the 
hospital? 
 _________________ hours 
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B Did anyone 
accompany you 
to the hospital 
during your last 
visit? 
 
Yes = 1 








because of this 
hospital visit? 
Yes = 1 
No = 2 
 
 
D On average 
how much did 
the 
accompanying 




 ___________ R 








B Do you pay out 
of pocket 





Yes = 1 
No = 2 
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 How much in 
total do you pay 










____________ R               
  Consultation  
(doctors visit) 
____________ R 
  Hospitalization 
(No of bed) 
____________ R 
  Drug supply ____________ R 
C how much was 
spent on. 
 Transport  
____________ R 
  Accommodation  ____________ R 
  Food cost ____________ R 
Da On average, 
how many 
hours/days of 
work did you 
miss during you 
visit to the 
hospital? 
 _________________ hours 
 
B Did anyone 
accompany you 
to the hospital 
Yes = 1 
No = 2 
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during your last 
visit? 
 
   




because of this 
hospital visit? 
Yes = 1 
No = 2 
 
 
D On average 
how much did 
the 
accompanying 




 ___________ R 










B Do you pay out 
of pocket 





Yes = 1 
No = 2 





 How much in 
total do you pay 
OOP for you 
 ___________________________R 





  Consultation  
(doctors visit) 
____________ R 
  Hospitalization 
(No of bed) 
____________ R 
  Drug supply ____________ R 
C how much was 
spent on, 
 Transport  
____________ R 
  Accommodation  ____________ R 
  Food cost ____________ R 
Da On average, 
how many 
hours/days of 
work did you 
miss during you 
visit to the 
hospital? 
 _________________ hours 
 
B Did anyone 
accompany you 
to the hospital 
during your last 
visit? 
 
Yes = 1 








Yes = 1 
No = 2 
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because of this 
hospital visit? 
 
D On average 
how much did 
the 
accompanying 




 ___________ R 
 
SECTION G: COPING STRATEGIES 
 QUESTION CODING 
CATEGORIES 
ANSWER 
G01 In the past year, have you ever had 
to take out a loan to pay for 
medical expenses related to RHD?” 
Yes =1  
 No = 2   
Don’t know=99       
 





G03 Does the loan have interest? Yes =1  
 No = 2   
Don’t know=99       
 
If No >> K06 
G04 What is the interest rate on the 
loan? (%) 
 __________% 
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G05 Did you receive gifts or financial 
assistance from friends and family? 
 
Yes =1  
 No = 2   
Don’t know=99       
 
G06 If answer to K06 is Yes, Was it a 











G07 Did your caregiver had to change 
their job or take another one in 
other to pay for your medical care? 
Yes =1  
 No = 2   
Don’t know=99       
 
G08 Did anyone in your family had to 
work extra hour to pay for the 
medical care? 
Yes =1  
 No = 2   
Don’t know=99       
 
G09 Does anyone have to drop out of 
school and take a job to assist in 
the payment? 
Yes =1  
 No = 2   
Don’t know=99       
 
ASSETS 
G10a Have you sold any of your property 
to finance the cost of the RHD 
illness? 
Yes =1  
 No = 2     
Don’t know=99           
 
G10b  If Yes, what did you sell?  
 
Land = 1 
Livestock = 2 
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Household item = 4 
Farm produce =5 
Other (specify): 
C What is the estimated market value 
of the property you sold? 
 __________________ 
R 
D  How much did you earn from the 
sale of your property? 
 __________________ 
R 
G11 Does the caregiver lose time when 
taking of RHD patient in this 
household? 
Yes =1  
 No = 2  
Don’t know=99            
 
 
If NO >> G13 
G12 How do you make up for the time 
loss? Please specify 
 _________ 
G13 Is there anything else you’d like to 
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